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Abstract: The aim of cardiac cell therapy is to restore at least in part the functionality of the diseased or injured myocar-
dium by the use of stem/progenitor cells. Recent clinical trials have shown the safety of cardiac cell therapy and encourag-
ing efficacy results. A surprisingly wide range of non-myogenic cell types improves ventricular function, suggesting that 
benefits may result in part from mechanisms that are distinct from true myocardial regeneration. While clinical trials ex-
plore cells derived from skeletal muscle and bone marrow, basic researchers are investigating sources of new cardiomyo-
genic cells, such as resident myocardial progenitors and embryonic stem cells. In this commentary we briefly review the 
evolution of cell-based cardiac repair, some progress that has been made toward this goal, and future perspectives in the 
regeneration of cardiac tissue. 
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INTRODUCTION 
 Congestive heart failure and coronary artery disease are 
the leading causes of morbidity and mortality in western 
society, despite recent advances in medical and device-based 
therapies. Limited strategies are available to address and 
counteract the central pathophysiologic process underlying 
the development of heart failure, which is the loss of cardio-
myocytes, permanently compromising myocardial contractile 
function [1-3]. The injured heart heals by scar formation 
rather than by cardiomyocyte regeneration. Heart regenera-
tion seems to be too inefficient to repair the extensive myo-
cardial injury that occurs in human disease. Heart transplan-
tation is currently the last chance for end-stage heart failure, 
but it is hampered by severe shortage of donor organs and 
rejection. Cell-based therapies are a promising alternative, 
given the basic assumption that left ventricular dysfunction 
is largely due to the loss of a critical number of cardiomyo-
cytes and therefore it could be partly reversed by implanta-
tion of new contractile cells into the post-infarction scar. 
During the last few years cellular therapy for the diseased 
heart, using a variety of different cells, has shown encourag-
ing results on cardiac function in animal models of heart 
ischemia, even without clear cardiovascular differentiation of 
the transplanted cells and without clear corresponding results 
in the first clinical trials.  
 In fact, while in the field of skin [4], cartilage [5], bone 
[6], adipose tissue [7, 8], and cornea [9], regenerative medi-
cine (including cell therapy) is already well established and  
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used clinically, therapeutic cardiac regeneration has to over-
come some hurdles to be clinically feasible. We still need to 
develop efficient methods to selectively induce differentia-
tion, to ensure cell yield, and to create transplantable tissue. 
The potential of cardiac cell therapy depends on the outcome 
of basic research and its application to the clinic. 
 In this review, a critical update will be presented on basic 
and clinical problems challenged by cardiac regenerative 
medicine, in particular by cell therapy. Furthermore, new 
perspectives on cardiac stem cells biology and their clinical 
deliverables will be discussed.  
CELLS EMPLOYED FOR EXPERIMENTAL CAR-
DIAC REGENERATION 
 The difficulty in regenerating damaged myocardial tissue 
has led researchers to explore the application of different 
stem cell types as possible sources for cell therapy, including 
embryonic stem cells (ESCs), cardiac stem cells (CSCs) that 
naturally reside within the heart, myoblasts (muscle stem 
cells), adult bone marrow (BM) derived cells, mesenchymal 
stem cells, endothelial progenitor cells, and umbilical cord 
blood cells. All have been tested in mouse or rat models, 
while some of them in large animal models as well, such as 
pigs, and in human clinical trials [10-14] (Table 1).  
 In the last five years the number of scientific publications 
concerning the experimental use of stem/progenitor cells for 
cardiac pathologies has grown up in a linear trend [15], with 
a slight decrease after 2006. This trend inversion reflects 
difficulties in finding adequate solutions to the many hurdles 
to be overcome for the clinical translation of a safe and ef-
fective cell therapy.  
 Many well-known problems exist and warrant further 
studies: the difficulty of inducing adult stem cells to cross 
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their lineage boundaries (skeletal myoblasts and BM cells do 
not appear to transdifferentiate into cardiomyocytes); the 
commitment degree, the survival and the long-term retention 
of the injected cells and their properties (affecting adequate 
engraftment, proliferation, migration, differentiation and 
functional integration with the host); the timing and delivery 
strategies, also related to the specific heart pathology and to 
the patient to be treated.  
 In this contest, the paper of Zeisberg [16], showing that 
cardiac fibrosis is associated with the emergence of fibro-
blasts originating from endothelial cells, could be considered 
a milestone because it addresses a process important for the 
critical evaluation of the long-term fate of any injected cell. 
In this study, in fact, TGF- release and endothelial-to-
mesenchymal transition have been suggested to contribute to 
the persistence of fibrosis, while BMP-7 was proposed as an 
inhibitor of the process, and therefore as a valuable therapeu-
tic tool. The same mechanism however could have a role in 
the temporary functional effect elicited by almost all kinds of 
injected cells, particularly those employed in clinical trials. 
Table 1. Stem Cell Populations Employed in Clinical Trials: Phenotype and In Vivo Results in Animal Models 
Stem Cell Population Phenotype In Vivo Results Controversial Issues Ref. 
Lin- / c-kit+ +    CMs 
+    SMCs 
+    ECs 
    LV function 
Massive regeneration 
independent of cell fusion.  
[99] 
[100] 
CD34- / c-kit+ / Sca1+ +    CMs 
?    SMCs 
+    ECs 
?    LV function 
Very low % of 
donor-derived cells. 
[101] 
 
Hematopoietic 
Stem Cells 
Lin- / c-kit+ or 
Lin- / c-kit- / Sca1+ 
-     CMs 
-     SMCs 
-     ECs 
?     LV function 
Trasplanted cells express 
hematopoietic markers. 
[102] 
[103] 
CD45- / CD105+ / 
CD73+ / CD90+ 
+    CMs 
+    SMCs 
+    ECs 
    LV function 
Transdifferentiation. [104] 
[105] 
[106] 
[107] 
Mesenchymal 
Stem Cells 
CD34- / CD45- / 
CD29+ / CD44+ 
+/?  CMs 
?     SMCs 
+     ECs 
     LV function 
Immature CM phenotype. [108] 
[109] 
-     CMs 
+    SMCs 
+    ECs 
     LV function 
Release of protective GFs. [110] 
[111] 
Endothelial 
Progenitor Cells 
CD34+ 
(G-CSF-mobilized) 
+     CMs 
+    SMCs 
+    ECs 
    LV function 
Vasculogenesis and 
cardiomyogenesis. 
[112] 
Skeletal Myoblasts No N-cadherin. 
No connexin43. 
Resistant to ischemia. 
-     CMs 
-     SMCs 
-     ECs 
     LV function 
Prevent LV remodelling (?) but 
induce arrhytmias. 
[113] 
[114] 
CMs: cardiomyocytes; SMCs: smooth muscle cells; ECs: endothelial cells; G-CSF: granulocyte-colony stimulating factor; LV: left ventricle; +: differentiate in; -: do not differentiate 
in; : improvement. 
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In other words, the cells to be used need to harbor a strong 
intrinsic and spontaneous potential of cardiac commitment, 
otherwise new scar will be added over the old one.  
 As previously suggested, the most appropriate cells for 
replacing dead cardiomyocytes appear to be cardiomyocytes 
of fetal or embryonic origin, since they can integrate func-
tionally with resident myocardial cells [17]. This view is 
supported by experiments showing that transplanted fetal 
cardiac cells successfully engrafted into myocardial scars, 
connected with their host neighbors and improved function 
[18]. Moreover, in a recent study, Caspi [19] has shown that 
grafting of human ESC-derived cardiomyocytes into the 
normal and infarcted heart did not result in the generation of 
teratomas, as it occurs using undifferentiated ES cells. In-
stead the engrafted cardiomyocytes were shown to survive, 
proliferate, and integrate with host cardiac tissue [19]. How-
ever cardiomyocytes can not differentiate into coronary ves-
sels, which obviously are also necessary for cardiac repair. 
Furthermore, their availability and scalability, in addition to 
immunological and ethical constraints, limit the use of fetal 
or embryonic tissue for any clinical application. Embryonic-
like stem cells can be derived from neonatal and adult sper-
matogonial stem cells [20]. These cells have cardiac differ-
entiation potential and could be used for autologous regen-
erative strategies without ethical and immunological prob-
lems [21]. Further studies are necessary to characterize these 
cells and to evaluate their behavior.  
 Another possible approach in cardiac repair concerns the 
use of mesothelial cells (MCs). MCs have an important role 
in the serosal homeostasis and repair after damage, and in 
preventing fibrous adhesion formation. Although MCs are of 
mesodermal origin, they show properties of both epithelial 
and mesenchymal phenotypes, displaying some degree of 
plasticity. MCs produce many cytokines and growth factors 
which can regulate inflammatory responses and stimulate 
tissue repair [22]. MCs also have the capacity to produce in 
vitro a variety of extracellular matrix macromolecules and to 
regulate their turnover [22]. 
 Due to their multiple features and their endothelial prop-
erties, MCs are also used in tissue engineering and have been 
recently proposed as a cell source for cardiac repair. When 
transplanted into the damaged myocardium, MCs induced 
neoangiogenesis in the infarct scar and preserved heart func-
tion [23].  
 However, future studies warrant to fully understand their 
potential role and benefits for cardiac cell therapy. 
 Remarkable advances are also being made in generating 
pluripotent embryonic-like stem cells from somatic cells by 
viral expression of specific ESC-related genes and by so-
matic cell nuclear transfer [24]. 
 The ideal cell to be transplanted for cardiac regeneration 
should probably be intermediate between a highly undiffer-
entiated phenotype (ESCs) and a terminally differentiated 
cardiomyocyte. It should be characterized by a defined pro-
liferative potential in the host without induction of immune 
reaction, by cardiac commitment and capacity to develop 
gap-junctions with the host cells, and should preferably be  
 
resistant to ischemia, in order to avoid massive cell death and 
apoptosis, that are currently among the biggest hurdles for 
cell therapy translation. 
 With these premises, it seems obvious that the best cells 
to replace lost cardiomyocytes may be cells derived from the 
heart itself. 
CARDIAC STEM CELLS AND CARDIAC REGEN-
ERATION 
 Emerging evidence suggests that several populations of 
stem/progenitor cells are present in the heart. A true cardiac 
stem/progenitor cell could be the ideal cell to repair a broken 
heart. However extensive basic research has yet to be per-
formed to better understand the biology of these cells, that 
will foster the development of cell-based therapies for heart 
disease. 
Evidence and Controversies on Mammalian Heart  
Regeneration 
 Typically, adult cardiac myocytes do not reenter the cell 
cycle when exposed to growth signals and further increase in 
cardiac mass during adulthood is achieved through hypertro-
phy. In contrast to most adult cardiomyocytes, fetal cardio-
myocytes do proliferate. After birth, cardiomyocytes become 
binucleated, and withdraw from the cell cycle. Therefore 
adult mammalian cardiomyocytes have very limited potential 
for self renewal; the mammalian heart has historically been 
viewed as a terminally differentiated organ.  
 However the following observations lead to suggest that 
the mammalian heart has some potential intrinsic capacity to 
regenerate: 
a. The presence of myocytes undergoing mitosis and cyto-
kinesis has been demonstrated in human hearts, espe-
cially under pathologic conditions (myocardial infarction, 
late cardiac failure) [25].  
b. Resident CSCs have been identified in the adult heart of 
humans and other mammal species (Table 2). These cells 
are self-renewing, clonogenic and multipotent, being able 
to differentiate into cardiomyocytes, smooth muscle and 
endothelial cells.  
c. From a very elegant genetic fate-mapping study [26], an 
indirect evidence has been obtained that an undefined 
population of stem/progenitor cells could replace adult 
mammalian cardiomyocytes after injury. In this study the 
authors used double transgenic mice, in which tamoxifen-
induceable Cre-recombinase was under the control of the 
MHC promoter, and a reporter cassette under the actin 
promoter. The reporter gene was lacZ flanked by lox-
sites, that would allow to switch to a GFP-reporter with 
induction of the Cre-recombinase. After a 4-OH-
tamoxifen pulse, GFP was expressed through the induc-
ible Cre-Lox system only in differentiated MHC-
expressing cells, resulting in ~80% of GFP+ cardiomyo-
cytes. After myocardial infarction (MI) or pressure over-
load, the percentage of GFP+ cardiomyocytes signifi 
cantly decreased, indicating that a putative stem/precur-
sor cells, had refreshed the cardiomyocyte pool. 
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 These studies indicate that, at least after injury, the heart 
has some limited capacity to regenerate and suggest that 
resident cardiac stem cells are involved in this process. 
 In the Hsieh study [26] it has been shown that in mice up 
to one year the percentage of GFP+ cardiomyocytes (that is 
the percentage of differentiated myocytes at the time of puls-
ing) remained unchanged, indicating no detectable replace-
ment of cardiomyocytes by progenitor cells during normal 
aging. This observation supports the traditional view that 
cardiomyocytes are very long-living in the adult heart, and it 
is against the suggestion that the heart is a self-renewing 
organ in which myocyte regeneration occurs throughout the 
organism lifespan [27, 28]. 
 However by following the 
14
C-dating of cardiac DNA, 
based on inadvertent pulse-labeling from atmospheric  
 
nuclear tests, it was demonstrated both in pre- and post-
atomic bomb born patients that, although the majority of 
cardiomyocytes are present from early development, their 
turnover is occurring during adulthood, at least until the third 
decade of life [29]. If cardiac regeneration occurs in the 
normal heart, the lack of detectable replacement of cardio-
myocytes by progenitor cells during aging in the study by 
Hsieh could be explained (provided that these discrepancies 
could not be attributed to technical or methodological arti-
facts) assuming that cardiomyocytes are able to divide. Al-
though it is generally accepted that cardiomyocytes loose 
their replicative capacity shortly after birth, it seems likely 
that the renewal of myocardial tissue during adult life might 
occur thanks to the ability of some cardiomyocytes to resume 
DNA synthesis and mitosis. This hypothesis is consistent 
with the observation that differentiated mononuclear cardio 
 
Table 2. Resident Cardiac Stem Cells 
Main Isolation 
Marker/Phenotype 
SP Phenotype  
(Hoechst 3342 Efflux) 
c-Kit Sca-1 CSp Phenotype SSEA-1 Isl-1 cKit/CD34 
Species mouse mouse mouse 
CD31 
rat human 
(Clones) 
mouse mouse/ 
human 
human rat neonatal  
rat 
mouse 
SSEA-1          +    
Oct-4  -        +    
Isl-1          +/- +   
cKit (CD117) - low - - + + - + +/- +/- - - + 
Sca-1 (Ly 6) - high + +   + + - +/- -  +/- 
MDR1(Abcb1,Pgp)         -    + 
Abcg2(MXR1,BCRP)  +       - +/-    
CD90 (Thy-1) -       + +/-   +/-  
CD133 (prominin)      -   -     
CD105 (endoglin)        + +   +/-  
CD34 - low - - - - - + +/-   +  
CD45 (LCA)  low - - - - -  - -  - - 
CD31 (PECAM-1)  - - +  - + +/- +/- -  -  
VEGFR2  
(KDR,Flk-1) 
     -  +  +    
Blood lineage markers     -  -  -     
Cardiac transcription 
factors 
 + +  + - + + + +/- + +/- +/- 
In vitro differentiation 
method 
- Cc Cc - DM DM 5-Aza Sp 
Cc 
Cc DM 
Cc 
Cc - - 
References [34] [35] [36] [37] [115] [39] [44, 45] [45] [42] [41] [43] 
+/-: subset; Cc: co-colture; DM: differentiating media; 5-Aza: 5-azacytidine;  
Sp: spontaneous. CSp: cardiosphere; SP: side population.  
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myocytes have some proliferative potential and reenter the 
cell cycle [30]. Adult cardiomyocytes of lower vertebrates 
(Anuria, Urodelia) proliferate considerably [31]. Zebrafish 
and newts hearts regenerate after injury with little or no scar 
formation. In newts regeneration occurs through de-
differentiation of specialized cells in blastema cells that 
redifferentiate afterwards into parenchimal cells [32]. In ze-
brafish, regeneration is supported by formation of blastema 
and by a subpopulation of epicardial cells [33]. Conversely 
the mammalian heart repairs itself poorly after infarction and 
regenerates poorly after injury. 
CSCs Discovery 
 The discovery that the heart is not a terminally differenti-
ated organ, but has a partial capacity to regenerate, gave a 
tremendous input in the last few years to the study of CSCs 
biology and increasing attention has been focused on the 
finding that the heart contains a reservoir of stem and pro-
genitor cells [34-45]. These cells are positive for various 
stem/progenitor cell markers (c-Kit, Sca-1, Isl-1) and have 
Side Population (SP) properties. Although the relationship 
between the various CSCs and progenitor cells described 
awaits clarification (Table 2), nevertheless, they promise 
new therapeutic strategies for cardiac repair based on their 
regenerative potential. In fact, their presence into the heart, 
the frequent co-expression of early cardiac progenitor tran-
scription factors, and the capability for ex vivo and in vivo 
differentiation towards the cardiac lineages offer the promise 
of enhanced cardiogenicity compared to other non-cardiac 
cell sources. 
 A well-known review by Garry and Olson [46] empha-
sizes a message shared by three recent studies [47-49], pro-
viding evidence for the existence during early development 
of cardiac progenitor cells that have the potential to differen-
tiate in the three major cell types of the heart: myocytes, 
smooth muscle and endothelial cells. Beside the importance 
of each individual study, they raise still unresolved questions 
(relationship between the different progenitors described, 
variables in defining the differentiation pathway, markers 
and so on), particularly those related to the methods em-
ployed.  
 Due to the limited knowledge concerning the regulatory 
networks of proliferation, self renewal and lineage differen-
tiation of cardiac progenitor cells, these studies tell us what 
is possible in our labs, but not necessarily what actually hap-
pens in vivo during development and disease. In other words, 
it is debatable to claim that one specific isolated cell is “the” 
only cardiac stem cell. 
Types of Resident Cardiac Stem and Progenitor Cells 
 Different methods have been used to isolate CSCs from 
the heart, based on: 
The Ability to Efflux Hoescht Dye (Side Population) 
 SP cells, which have the ability to efflux Hoechst dye, a 
process dependent on the expression of MDR1, Abcg2 or a 
comparable ABC transporter, have been identified in the 
developing, but also in the adult heart of mice [34, 35]. 
These cells are rare and their ability to differentiate into con-
tracting cardiac myocytes or to contribute to functional re-
pair of damaged heart muscle has not been extensively 
evaluated yet. Among cardiac SP cells, the greatest potential 
for cardiomyogenic differentiation is restricted to cells nega-
tive for CD31 and positive for stem cell antigen 1 (Sca1) 
expression [36]. 
The Presence of Cell-Surface Stem Cell Markers (Either c-
kit or Sca-1) 
 In adult rat hearts a distinct population of CSCs has been 
isolated. These relatively small and primitive cells are nega-
tive for blood lineage markers and positive for c-kit, the re-
ceptor for the stem cell factor. These cells are self-renewing, 
clonogenic, and multipotent, giving rise to cardiomyocytes, 
smooth muscle and endothelial cells. When injected into the 
border zone of a 5-hour-old infarct in adult rats, these CSCs 
differentiated into newly formed myocardium, including 
cardiomyocytes, capillaries and arterioles in the infarcted 
area [37]. When delivered in a clinically relevant manner by 
intracoronary injection after a 90-minute coronary occlusion, 
followed by 4-hour reperfusion in rats, CSCs reduced the 
infarct, attenuated myocardial remodeling and ameliorated 
cardiac dysfunction 5 weeks after MI [38].  
 In the non-myocyte fraction of mice hearts, a resident 
population of CSCs, characterized by the expression of Sca-
1, but lacking blood lineage markers or c-kit, has been re-
ported [39, 40]. Even though these cells do not spontane-
ously differentiate in vitro, when exposed to 5-azacytidine 
[39] or oxytocin [40] a small fraction of them demonstrates 
biochemical evidence of cardiac myocyte differentiation. 
After intravenous injection in mice subjected to myocardial 
ischemia-reperfusion, Sca-1+ cells homed to the heart and 
differentiated into cardiomyocytes, in part because of fusion 
with host cells [39].  
Expression of the Islet-1 Gene (isl1+ Cells) 
 Another population of CSCs, characterized by the ex-
pression of the LIM-homeodomain transcription factor islet-
1 (isl1+ cells), has been recently described. These cells re-
side in the mature heart of newborn mice, rats and humans, 
and they are negative for c-kit or Sca-1, but express the early 
cardiac transcription factors Nkx2.5 and GATA4. When co-
cultured with cardiomyocytes, isl1+ cells convert very effi-
ciently to mature cardiomyocytes without cell fusion [41]. 
However, their low abundance and mere presence in very 
young animals and humans prevent their short-term applica-
tion. A challenge regarding this cell population is whether 
isl1+ cells are present in the adult heart and whether they 
can be isolated, expanded, induced to differentiate or if they 
are able to regenerate damaged myocardium in vivo. 
Expression of the Stage-Specific Embryonic Antigen 
(SSEA-1+ Cells) 
 Recently uncommitted cardiac precursor cells (UPCs) 
have been identified in the heart of adult rats through a typi-
cal embryonic antigen, SSEA-1, that is expressed early in 
heart development [42]. SSEA-1+ cells isolated from adult 
rats differ from neonatal cells because they do not express 
cardiac specific transcription factors (Nkx2.5, GATA4). This 
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suggests that only uncommitted stem cells persist in the adult 
heart. Adult UPCs in co-culture with cardiac-derived mesen-
chymal cells can differentiate in mature cardiomyocytes, 
endothelial cells, and smooth muscle cells through multiple 
stages, in which the cells co-express markers such as Oct4, 
Flk-1 or Sca-1 together with SSEA-1. Then, once commited, 
they finally express cardiac transcription factors such as 
Nkx2.5, GATA4 and Isl-1. Beating colonies are obtained by 
culturing UPCs in differentiating media or in co-culture with 
neonatal cardiomyocytes. UPCs improved ventricular func-
tion when injected in infarcted hearts, and SSEA-1+ cells are 
capable of forming new cardiomyocytes and endothelial cells 
in the infarct area [42]. 
Epicardially Derived Cells (EPDCs) 
 Limana [43] first identified cardiac progenitor cells out-
side of the previously described “niche” in human and mouse 
epicardium, which can migrate into the sub-epicardium 
where they generate a population of EPDCs. The authors 
described two distinct populations of myocardial and vascu-
lar precursor cells, expressing c-Kit or CD34 respectively 
[43]. Although c-Kit+ and CD34+ cells are negative for 
haematopoietic and endothelial markers (CD45-, CD31-), 
both populations have the ability to acquire the endothelial 
phenotype, as demonstrated by their capacity to uptake Ac-
LDL-DiI, which is considered to be a specific marker for 
endothelial cells. A subset of c-Kit+ and CD34+ cells ex-
press cardiac transcription factors (Nkx2.5, GATA4). Their 
differentiation potential has been demonstrated only for c-
Kit+ cells when a MI was induced in the mouse in the pres-
ence of an intact pericardial cavity.  
Cardiospheres: A Novel Method to Isolate CSCs 
 Messina first debugged a methodology to isolate CSCs 
by primary culture of murine hearts or human heart tissue 
fragments derived from open heart surgery [44] (Fig. (1)). 
After few weeks of culture, a heterogeneous population of 
cells shed spontaneously from tissue fragments. Cells sur-
rounding the “explants” express stem cell markers (c-Kit, 
Sca-1), endothelial progenitor cell antigens/markers (KDR, 
CD31) and the gap-junction protein Connexin43 (Cx43). 
They are clonogenic, and multipotent, giving rise spontane-
ously to cardiomyocytes, smooth muscle and endothelial 
cells. In suspension culture they form spherical multicellular 
clusters dubbed “cardiospheres” (CSps). CSps consist of 
proliferating c-Kit-positive cells primarily in their core, and 
of differentiating cells expressing cardiac (MHC, NKx2.5, 
TnI, ANP), vascular (SMA), endothelial (vWF) and 
mesenchymal (CD105, CD90) cell markers on their 
periphery [44, 45]. 
 The 3D-structure of CSps probably resembles the actual 
architecture of cardiac tissue, in terms of intra- and extra-
cellular interactions, which may have a fundamental role in 
regulating cellular functions such as proliferation, differen-
tiation and angiogenesis. In fact, differently from CSCs iso-
lated with other methods, CSps can lead to terminally differ-
entiated cardiomyocytes, as demonstrated by their ability to 
beat, either spontaneously (embryonic and neonatal murine 
CSps) or after co-culture with rat neonatal cardiomyocytes 
(pig, human, adult mice CSps). Moreover it seems likely that 
the protective microenvironment of the CSps could enable 
stem cells (or cells with stem-cell function) to retain their 
potency, as in the “niche” [50]. 
 It has not yet been determined which are the antigens that 
could unequivocally identify CSp-forming cells. Experi-
ments carried out using transgenic mice suggest that c-kit 
positive cells have a major role in CSps formation and 
growth. Although the intracardiac origin of CSCs and adult 
myocytes is generally accepted, GFP+ CSps were obtained 
3-4 weeks after heart injury in lethally irradiated mice, 
whose BM had been repopulated by haematopoietic cells 
from a syngeneic c-kit/GFP animal [51]. This suggests that, 
at least under these conditions, BM cells could replenish the 
cardiac c-kit+ stem cell pool, acquiring functional character-
istics of specialized CSCs, such as the capability to form 
CSps. 
 In order to increase cell yield, CSps can be expanded as 
adherent monolayers on fibronectin. Between 10 and 100 
million cells can be obtained from a single biopsy in about 
45 days [45]. Transplantation of human CSp-derived cells 
(CDCs) in the peri-infarct zone of SCID mice led to en-
graftment, migration, proliferation and multilineage differen-
tiation, resulting in the replacement of dead tissue with new 
 
 
 
 
 
 
 
 
Fig. (1). Cardiosphere isolation steps. Explants are plated as primary cultures, and cells migrate from tissue fragments (A). CSp-forming 
cells are collected from the explant and then they spontaneously form floating CSps (B). 
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myocardium and in functional improvement after 3 weeks 
[45].  
 There are many characteristics that make CSps different 
from other kinds of CSCs populations which have been iso-
lated so far, in particular from those isolated by selection of a 
single putative stem cell marker. 
• The CSp isolation protocol is based on intrinsic and 
spontaneous functional properties of the cells, which are 
the ability to migrate from tissue explants and to grow as 
3D-structures, resembling somehow a niche-like micro-
tissue. 
• CSps can lead to terminal differentiation: embryonic and 
neonatal murine CSps can start beating spontaneously, 
while other CSCs need the addition of differentiating 
agents and/or co-culture with cardioyocytes in order to do 
so. 
• CSps represent a heterogeneous population, including c-
kit positive stem-like cells and other cell types expressing 
mesenchymal markers: these latter, beside endothelial 
and fibroblast phenotypes, might also have a feeder-layer 
role, allowing the activation of multiple mechanisms for 
cardiac repair beyond myocyte formation (paracrine pro-
survival effects, angiogenesis, mobilization of endoge-
nous CSCs). 
TISSUE ENGINEERING 
 In the past few years, cardiac tissue engineering (CTE) 
has emerged as a new approach to regenerate hearts damaged 
by myocardial infarction. CTE combines the use of biomate-
rials with cell biology and medicine. Several tissue engineer-
ing approaches are being explored for cardiac repair. In this 
review we briefly present an overview on the most promising 
materials and interesting approaches employed for CTE (for 
a complete review see Zamaretti [52], Zimmerman [53] and 
Jawad [54]). 
 The ideal biomaterial for CTE, either synthetic or natural, 
should enhance cell attachment, growth and differentiation. 
Moreover it should promote revascularization and have elet-
tro-mechanical properties, allowing good integration with 
heart tissue. The most common approach for CTE is to seed 
cardiomyocytes onto pre-formed porous scaffolds made of 
polylactic acid, polyglycolic acid and their co-polymer poly-
lactic-co-glycolic acid [55]. Other synthetic materials used in 
CTE are 1,3-trimethylene carbonate, D-L-lactide and their 
co-polymers [56], or the co-polymers -caprolactone-co-L-
lactide [57, 58].  
 A very exciting approach is the cell-sheeting method that 
involves cell culturing on temperature-responsive culture 
dishes. These dishes are made of poly-(N-isopropylacryla- 
mide) (PIPAAm), which at 37°C is hydrophobic and pro-
motes cell attachment. When temperature decreases to 32°C 
the polymer becomes hydrophilic and the cell sheet detaches 
from the plate. Shimizu et al. demonstrated that the detach-
ing cell layers can be collected and, when layered one on top 
of the another, the sheets fuse, beat synchronously and be-
come vascularized in vivo [59-61]. 
 Several groups are currently working with scaffold mate-
rials made of natural polymers such as collagen, gelatin and 
alginate. Zimmermann et al. used a combination of liquid 
collagen type I and matrigel with neonatal cardiac myocytes 
cultured in persistent mechanical load [62, 63]. Other ap-
proaches utilized a pre-formed, commercially available, tri-
dimensional collagen matrix, obtaining promising results in 
terms of cardiac remodelling after implantation in an in vivo 
model of MI [64-70]. 
 Chachques et al. reported the safety and feasibility  
of treatment with BMCs seeded onto a 3D collagen-type  
I-matrix in patients with left ventricular post-ischemic myo-
cardial scar. The cell-seeded collagen matrix prevents car-
diac remodeling and increases the thickness of the infarct 
scar with viable tissue, improving cardiac function [69, 71]. 
 Another method that has emerged in the last years is  
an in situ CTE approach that involves injection of a mixture 
of biomaterials and cells. An example of this type of  
approach is the fibrin glue scaffold, consisting of two com-
ponents: the first one consists of concentrated fibrinogen and 
aprotinin, and the second contains thrombin, CaCl2 and cells. 
When delivered in vivo with a Duploject applicator, that pro-
vides simultaneous mixing and delivery, the two compo-
nents form a solid gel matrix that supports neo-angiogenesis, 
cell survival and decrease in infarct size [72, 73]. Other natu-
ral biomaterials used with this kind of approach are collagen 
I [74-77] and matrigel [74, 77, 78]. Finally a similar ap-
proach was applied by Davis et al. that injected “self assem-
bling” peptide nanofibers into the myocardium for recruit-
ment of progenitor cells and promotion of vasculogenesis 
[79]. 
Clinical Trials  
 Although experimental studies with BM stem cells in 
animal models gave rise to controversial results in terms of 
cardiac trans-differentiation and regeneration, they have been 
employed in several human clinical trials that took place in 
the last few years, and most of them are undergoing clinical 
evaluation (Table 3). BM is, at present, the most frequently 
used source of cells for clinical cardiac repair. In most clini-
cal trials BM-derived cells or peripheral blood progenitor 
cells were transplanted both in patients with acute MI and 
chronic ischemic cardiomyopathy. Cell number, administra-
tion route and time of delivery also differed among studies. 
BM stem cells have been delivered in three ways, depending 
on the disease and pathological status of the patients: intra-
coronary cell delivery, catheter-based endocardial injection 
or direct intramyocardial implantation during open heart 
surgery [80-82].  
 All studies showed an excellent safety profile that was 
associated with a modest-to-low improvement in ventricular 
function, and only in few cases the injection of BMCs re-
sulted in a consistent functional benefit (Table 4). Generally 
the advantage of intracoronary infusion is that cells migrate, 
via the microcirculation, to the perfused infarct region in a 
favourable environment for their survival, and this is a pre-
requisite for stable engraftment. On the other side, it limits 
their delivery only to the perfused regions and requires an 
increased number of cells to be administered. Moreover the  
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Table 3. Protocol Details of Some of the Completed Clinical Trials for Cardiac Cell Therapy 
Study 
Name 
N° of  
Patients 
Cell type/ 
Treatment 
Number of 
Cells (*10 
6 
) 
Delivery 
Route 
Infusion Time 
d= Days; 
m= Months; 
y= Years 
Rand. Follow-up 
(Months) 
Main  
Endpoints 
Strauer et al. 
[116] 
10 BMMNCs 28 Intracoronary 5-9 d. post MI - 3 Safety 
TOPCARE-AMI 
[95, 96] 
59 CPCs/BMCs 18-213 Intracoronary 4.9+/-1.5 d. post MI +/- 4-12 Safety and  
feasibility 
TOPCARE-CHD 
[117, 118] 
23+34+ 35 CPCs/BMCs 22+/-11 CPCs 
205+/-110 
BMCs 
Intracoronary MI> 3 m. + 3-6 LVEF 
REPAIR-AMI 
[119, 120] 
101+103 BMCs 50 ml BM  
aspirate 
Intracoronary 3-7 d. post MI + 4-12 LVEF 
BOOST [97, 98] 30+30 BMMNCs 2.46 Intracoronary 4.8+/-1.3 d. post MI + 6-18 LVEF 
Fernandez-Aviles 
et al. [121] 
20 BMMNCs 78 +/- 41 Intracoronary 13.5+/-5.5 d. post MI - 6 Safety and  
feasibility 
IACT study [122] 18 BMMNCs 6*15-22 Intracoronary 5 m.-8.5  y. post MI - 3  
Janssens et al. 
[123] 
33+34 BMMNCs 304+/-128 Intracoronary 2-3 d. post MI + 4 LVEF 
ASTAMI  
[124, 125] 
50+50 BMMNCs 54-130 (inter-
quartile range) 
Intracoronary 4-8 d. post M.I + 6 LVEF, LVEDV 
and infarct size. 
Chen et al. [126] 34+35 MNCs 6ml*(8000-
10000cells/ml) 
Intracoronary 18 d. from PCI + 3-6 LVEF 
Katritsis et al. 
[127] 
11+11 MSCs+EPCs 1-2 Intracoronary 242d.<MI <3y. - 4 Scar size 
Tse et al. [128] 8 BMMNCs 15 injection;  
107 cells/mL 
Endomyocardial severe I.H.D. - 3 Safety and  
feasibility 
Perin et al. [129] 14+7 BMMNCs 25.5+/- 6.3 Endomyocardial end-stage I.H.D. - 2-4 Safety 
Perin et al. [130] 11+9 BMMNC 15*2 Endomyocardial end-stage I.H.D. - 2-6-12 Safety and  
efficacy 
Fuchs et al. [131] 10 unfractionated 
ABM 
2,4ml*(32.6+/-
27.5) cells/ml 
Endomyocardial angina III-IV rev 
ischemia 
- 3 Safety and  
feasibility 
Stamm et al. 
[132, 133] 
12 BMCs; AC133+ 1.5 Open heart 
surgery (CAGB) 
10 days <MI< 3 
months 
- 3-10 
 
Safety and  
feasibility 
Li et al. [134] 6+30 BMMNCs 50-100 Open heart 
surgery (CAGB) 
concomitant with 
CAGB 
 1-12 Safety and  
feasibility 
MAGIC  
[135, 136] 
10+10+ 7 G-CSF mobilized 
PBSCs 
1500+/-500 Intracoronary MI>48 h or clinically 
stable CMI 
+ 6 Safety and  
feasibility 
Erbs et al. 
[137, 138] 
14 G-CSF  
mobilized CPCs 
69+/-14 Intracoronary after CTO + 3 Safety and  
feasibility 
Boyle et al. [139] 5 G-CSF  
mobilized CD34+ 
66.9+/-17.6 Intracoronary CIHD - 12 Safety and  
feasibility 
Ozbaran et al. 
[140] 
6 G-CSF mobilized 
PBSCs 
13-80 Open heart 
surgery (CAGB) 
Congestive heart 
failure 
- 4 Safety and  
feasibility 
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Table 3. Count…. 
Study 
Name 
N° of  
Patients 
Cell type/ 
Treatment 
Number of 
Cells (*10
6
 ) 
Delivery 
Route 
Infusion Time 
d= Days; 
m= Months; 
y= Years 
Rand. Follow-up 
(Months) 
Main  
Endpoints 
Pompilio et al. 
[141] 
4 G-CSF mobilized 
AC133+ 
13-200 Open heart 
surgery (CAGB) 
10 days <MI< 3 
months 
- 3-6 Safety and  
feasibility 
Losordo et al. 
[142] 
24 G-CSF mobilized 
CD34+ 
0.05 - 0.1 - 0.5 
cells/kg b.w. 
Endomyocardial Angina III-IV + 3-6 Safety and  
feasibility 
Briguori et al. 
[143] 
10 CD34+ 90-140 Intramyocardial Angina III-IV - 1-3-6-12 Safety and  
feasibility 
FIRSTLINE-
AMI [83, 84] 
25+25 G-CSF 10g/kg 
b.w. 6 days 
None Subcutaneous 85+/- 30 min. after 
PCI 
+ 4-12 Safety and  
efficacy 
G-CSF STEMI 
[85-87] 
39+39 G-CSF 10g/kg 
b.w. 6 days 
None Subcutaneous 1-2 d. after acute ST 
elevation 
+ 6 change in systolic 
wall thickening 
REVIVAL-2 [88] 56-58 G-CSF 10g/kg 
b.w. 5 days 
None Subcutaneous 5 d. after MI + 4 to 6 LV size and  
LVEF 
Pagani et al. [90] 5 myoblasts 300 Open heart 
surgery 
concomitant with 
LVAD implantation. 
-  Immunohisto-
chemical staining 
Menaschè et al. 
[89] 
10 myoblasts 871 Open heart 
surgery 
concomitant with 
CAGB 
- 10.9 +/-4.5 Safety and  
feasibility 
Herreros et al. 
[144, 145] 
12+14 myoblasts 200 Open heart 
surgery 
MI>4 w. concomitant 
with CABG. 
- 3-12 Safety and  
feasibility 
Siminiak et al. 
[146] 
10 myoblasts 0.4-50 Open heart 
surgery 
MI>3 m. concomitant 
with CABG. 
- 12 Safety, feasibility 
and efficacy 
Dib et al. [147] 30 myoblasts 10-30-100-300 Open heart 
surgery 
concomitant with 
LVAD or  CAGB 
- 4 years Safety and  
feasibility 
Smits et al. [148] 5 myoblasts 196+/-105 Endomyocardial MI> 4 w. - 3-6 Safety and  
feasibility 
Ince et al. [149] 6+6 myoblasts 210±150 Endomyocardial MI> 4 w. - 12 Safety and  
feasibility 
POZNAN [150] 10 myoblasts <100 Percutaneous 
transcoronary 
venous 
MI> 3 m. - 12 Safety and  
feasibility 
BMMNC: bone marrow mononuclear cell; CPC: circulating progenitor cell; EPC: endothelial progenitor cell; MSC: mesenchymal stem cell; GCSF: granulocyte colony stimulating 
factor; PBSC: peripheral blood stem cell; IHD: ischemic heart disease; CIHD: chronic ischemic heart disease; LVAD: left ventricular assist device; CAGB: coronary artery bypass 
grafting; CTO: recanalization of chronic coronary total occlusion; PCI: percutaneous coronary intervention; Rand: randomization. CMI: chronic myocardial infarction.  
 
outcome after intracoronary route may be negatively affected 
by cell uptake from the circulation or by embolic risk. An-
other approach is to deliver cells directly into the scar tissue 
by catheter-based injection or during open heart surgery by 
multiple direct injections. However these methodologies are 
limited by the risk of ventricular perforation and they may 
induce arrhythmias.  
 A different approach is that of enhancing CSCs and pro-
genitors activation and inducing their migration toward the 
infarct region by treatment with G-CSF. The rationale of this 
methodology derives from multiple studies in animal models 
(Table 1) and requires, for successful results, the reperfusion 
of the ischemic site. Briefly if we analyze different random-
ized trials with G-CSF treatment after acute myocardial in-
farction, discrepancies arise again about the real beneficial 
effect on cardiac function [83-88]. Unfortunately, despite 
many relevant clinical trials have used BM stem cells or their 
mobilization, once again relevant doubts still remain about 
the therapeutic efficacy of these cells for cardiac regenera-
tion (Table 4). 
 Autologous skeletal myoblasts are another potential 
source for cardiac repair. Skeletal myoblasts (SMs), or satel-
lite cells, are the reservoir of regenerative cells for the skele-
tal muscle. SMs feature several attractive characteristics as 
therapeutic cells, including the autologous origin, which 
overcomes immunologic and ethical concerns. They can be  
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Table 4. Improvement in Ventricular Function in Some Clinical Trials with Control Group 
Study Treatment/ 
Follow-up 
LVEF% LVESV LVEDV 
months Baseline 4 12 baseline 4 12 baseline 4 12 
control 46.9± 10.4 49.9± 13.0 75± 32 80± 45 139± 46ml 153± 57ml 
REPAIR-AMI  
[119, 120] 
BMCs 48.3± 9.2 53.8± 10.2 
Clinical 
outcome 
67± 26 67± 30 
Clinical 
outcome 
128± 38ml 141± 43ml 
Clinical 
outcome 
months Baseline 6 18 baseline 6 18 baseline 6 18 
control 51.3± 9.3 52.0± 12.4 54.4±13.0 40.6±16.9 
ml/m2 
42.6± 23.5 
ml/m2 
41.0±24.7 
ml/m2 
81.4± 16.9 
ml/m2 
84.9± 21.9 
ml/m2 
85.0± 24.2 
ml/m2 
BOOST [97, 98] 
BMCs 50.0± 10.0 56.7± 12.5 55.9±14.7 43.0±14.7 
ml/m2 
42.4± 23.9 
ml/m2 
42.5±25.0 
ml/m2 
84.2± 17.2 
ml/m2 
91.7± 26.0 
ml/m2 
90.3± 26.5 
ml/m2 
months Baseline 4 baseline 4 baseline 4 
control 46.9± 8.2 49.1± 10.7 44.4± 12.3 
ml/m2 
45.0±17.9 ml/m2 83.1± 14.7 
ml/m2 
85.9± 19.5 ml/m2 
Janssens et al. [123] 
BMCs 48.5± 7.2 51.8± 8.8 42.2± 10.5 
ml/m2 
41.0 ±15.5 ml/m2 81.2 ± 14.0 
ml/m2 
84.1± 20.8 ml/m2 
months Baseline 3 6 * baseline 3 6 baseline 3 6 
control 43± 13 42± 13 55± 36 ml/m2 55± 32 
ml/m2 
- 90± 38 ml/m2 87± 33 
ml/m2 
- 
CPCs 39± 10 39± 10 62± 31 ml/m2 60± 26 
ml/m2 
- 96± 34 ml/m2 93± 30 ml/m2 - 
TOPCARE-CHD 
 [117, 118] 
* = crossover to  
another group 
CTR BMC/CPC 
CPCs BMCs 
BMCs CPCs BMCs 41± 11 43± 10 
Improve-
ment mainly 
in BMCs 
treated. 
49± 26 ml/m2 47± 26 
ml/m2 
- 79± 29 ml/m2 79± 29 ml/m2 - 
months Baseline 6 Baseline 6 Baseline 6 
control 46.9± 9.6 48.8± 10.7 - - 132.0± 34.6 142.7± 45.2 
ASTAMI [124, 125] 
BMCs 45± 9.4 49.0± 9.5 - - 136.1± 30.5 145.0± 42.0 
months Baseline 3 6 baseline 3 6 baseline 3 6 
control 48± 10 53± 18 54± 5 88± 19ml 162± 27ml 
Chen et al. [126] 
MSCs 49± 9 67± 11 67± 3 
No difference 
between 
groups 
63± 20ml 
- No difference 
between 
groups 
136± 31ml 
- 
months Baseline 4 baseline 4 baseline 4 
control 46.18± 7.37 47.72± 6.46 62.3 ± 29.4 59.23± 21.35 121.2± 35.2 115.32± 26.75 
Katritsis et al. [127] 
MSCs+ EPCs 41.5± 7.7 43.45± 6.65 69.1 ± 24.0 65.27± 26.49 128.0± 36.0 119.45 ± 36.98 
months baseline 2 baseline 2 baseline 2 
control 36± 11.73 31.85± 7.55 89.42± 26.23 
cc 
98.85± 20.52 cc 135.71±  
26.08 cc 
145± 27.62 cc 
Perin et al.[129] 
BMCs 30± 5.56 35.5± 7.85 146.78± 
53.46 cc 
123.21± 47.88 cc 211.35±  
76.89 cc 
189.14± 67.54 cc 
LVEDD month baseline 4 12 - - - 
baseline 4 12 
control 47± 5 42± 4 45± 8 - - - 55± 4mm 59± 4mm 58± 4mm 
FIRSTLINE-AMI  
[83, 84] 
G-CSF 48± 4 54± 8 56± 9 - - - 55± 3mm 54± 5mm 54± 5mm 
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Table 4. Count…. 
Study Treatment/ 
Follow-up 
LVEF% LVESV LVEDV 
months Baseline 3 baseline 3 baseline 3 
control 44± 9 49.5± 12 87± 21ml 85± 44 ml 149± 32 ml 162± 52 ml 
G-CSF STEMI [85-87] 
 
G-CSF 4± 12 47± 12 83± 38 ml 79± 46 ml 140± 44 ml 145± 61 ml 
months Baseline 4 to 6 Baseline 4 to 6 Baseline 4 to 6 
control 49.2± 8.7 51.2± 9.0 46.1± 13.7 
ml/m2 
43.7± 17.5 ml/m2 89.6± 17.5 
ml/m2 
87.8± 21.9 ml/m2 
REVIVAL-2 [88] 
 
G-CSF 51.3± 8.2 51.8± 7.7 46.1± 15.2 
ml/m2 
45.5± 15.5 ml/m2 93.3± 18.7 
ml/m2 
92.4± 20.5 ml/m2 
months Baseline 12 baseline 12 baseline 12 
control 33.4± 9.1% 38.6± 11 141± 68.3ml 125± 55.8ml 221± 101ml 223± 64.1ml 
Herreros et al.  
[144, 145] 
myoblasts 35.6± 2.3% 55.1± 8.2% 99.1±26.8ml 69.1± 15.8ml 175± 39.3ml 166.1± 30ml 
LVEDD months Baseline 12 - - 
baseline 12 
control 24.7± 4.6 21.0± 4.0 - - 68.3± 4.9 mm 72.3± 5.0 mm 
Ince et al. [149] 
myoblast 24.3± 6.7 32.2± 10.2 - - 67.5± 6.0 mm 65.2± 6.0 mm 
BMCs: bone marrow cells; CPCs: circulating progenitor cells; MSCs: mesenchymal stem cells; LVEF: left ventricle ejection fraction; LVESV: left ventricle end-systolic volume; 
LVEDV: left ventricle end-diastolic volume; LVEDD: left ventricle end-diastolic diameter. 
 
readily isolated from relatively small skeletal muscle biop-
sies and amplified in an undifferentiated state in vitro. Prom-
ising experimental data in animal models of heart failure 
have led to several clinical trials, since June 2000 [89]. Al-
though clinical trials have shown cell survival, differentia-
tion toward a skeletal phenotype [90, 91] and improvement 
of global cardiac function following myoblasts injection 
(Table 3), they have also raised the issue of potential ar-
rhythmogenicity [92]. Myoblast grafts represent arrhyth-
mogenic foci because their electromechanical integration is 
limited by their inability to form gap-junctions [93], and also 
by their dihydropyridine phenotype, which markedly differs 
from that of cardiomyocytes. Myoblasts transplantation re-
sults in isolated islands of skeletal muscle tissue, mostly sur-
rounded by scar tissue, so re-entry circuits can be formed and 
cause arrhytmias. It has also been proposed that some trans-
planted myoblasts might fuse with cardiomyocytes, thereby 
generating heterogeneity in calcium-signalling at the graft-
host interface [94].  
 Generally the safety of cardiac cell therapy is well estab-
lished, as well as its beneficial effects in terms of neovascu-
larization and ventricular remodelling. However, long-term 
follow-up in most trials has shown that conventional phar-
macological therapy has often the same outcome of cellular 
therapy [95-98] which probably works through indirect 
mechanisms. For example, it might decrease the death rate of 
the existing myocytes, improve neoangiogenesis or posi-
tively affect ventricular remodelling. The details of the pos-
sible mechanisms are unknown, but they could involve 
growth factors and cytokines secreted by the injected cells. 
The small improvement in ventricular function though, espe-
cially in the long-term follow-up, is probably due to the in-
ability of the cells to actually form new cardiomyocytes. It is 
also important to notice that all the differences in the trials 
protocols (number of injected cells, reperfusion time be-
tween ischemia and therapy, etc.) make it difficult to directly 
compare them one to the other.  
CONCLUDING REMARKS 
 Extensive basic and clinical research performed during 
the last few years on cardiac regeneration and on the use of 
cell therapy to repair a broken heart led to two new important 
emerging concepts.  
 First, a large number of animal studies and clinical trials 
with different adult stem cells suggest that improved physio-
logical function does not necessarily mean myocardial re-
generation. After transplantation of non-cardiac cells that do 
not appear to transdifferentiate into new beating cardiomyo-
cytes, beneficial functional effects have been observed. The 
potential mechanisms leading to improvement are highly 
debated and might involve reduction in ventricular remodel-
ing after MI and/or paracrine effects that stimulate cell sur-
vival and angiogenesis. Considering the experience from the 
published clinical trials with non-cardiac stem/progenitor 
cells, a step backward to basic research study needs to be 
performed to better understand the real potential of the cells 
we are handling. In this regard, extensive studies have yet to 
be performed to better understand and control the self-
renewal and differentiation of these cells. Such knowledge 
could also be valuable to establish how to recruit CSCs al-
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ready residing in the heart by stimulating their proliferation 
and differentiation.  
 The second concept is that several subpopulations of car-
diac stem/progenitor cells reside within the adult heart. 
These cells are self-renewing, clonogenic and multipotent, 
being able to differentiate into cardiomyocytes, endothelial 
and smooth muscle cells both in vitro and in vivo. The rela-
tionship between the various cardiac stem/progenitor cells 
described awaits clarification through comprehensive charac-
terization and correlation of their origin, maintenance, and 
inherent reparative potential. Even if unable of massive re-
generation, nonetheless these cells seem to participate in 
some kind of spontaneous attempt of heart regeneration after 
myocardial injury. However their ability to replace dead car-
diomyocytes during normal aging has been questioned by a 
recent genetic fate-mapping study [26].  
 Theoretically a true cardiac progenitor cell would be the 
ideal cell type for the repair of a broken heart. Stem cells 
derived from a patient’s own heart represent an attractive 
source for cellular transplantation and myocardial regenera-
tion therapy. They are easily obtained in sufficient number 
from biopsy specimens and are capable of proliferation and 
differentiation into functional cardiomyocytes and vascular 
cells. Additionally, autologous CSCs can be used without 
immunosuppression. The possibility of using cardiac biopsy 
specimens as a source for ex vivo isolation and expansion of 
CSCs was introduced for the first time by our group [44, 45]. 
The expansion ex vivo over a period of weeks is necessary to 
obtain a sufficient number of cells for experimental and 
clinical purposes. Human CSCs, in the features of CSps or 
CDCs, injected into the infarct border zone of SCID mice, 
promoted cardiomyocyte and vessels formation, and im-
provement in systolic function. Therefore, human CSps and 
CDCs represent attractive cell sources for cardiac repair, and 
display unique characteristics among CSCs. Because both c-
kit-positive cells and cells that express mesenchymal mark-
ers are present in CSps, they have the potential ability to 
improve function through several mechanisms. Indeed, in 
addition to new cardiomyocyte formation, improvements in 
cardiac function and increased regeneration within the infarct 
area could be attributed to paracrine effects, increased mobi-
lization of endogenous CSCs and formation of new blood 
vessels.  
 Future clinical trials that will use stem cells for myocar-
dial repair must focus at least on three concerns that are re-
lated to the delivery of these cells: 1) safety, 2) cell tracking 
to their ultimate destination(s) and 3) cost-efficiency ratio. 
While cell tracking technologies allow researchers to follow 
their migration patterns, stem cells must safely target their 
destination(s) and be retained there for the required time to 
achieve benefit. To facilitate targeting and enable clinical 
use, stem cells must be delivered easily and efficiently to 
their sites of application. Finally, the ease and the cost neces-
sary for cell isolation and preparation will also impact the 
transition to the clinic of cardiac cell therapy. 
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ABBREVIATIONS 
ANP = Atrial natriuretic peptide 
BM = Bone marrow 
CDC = Cardiosphere derived cell 
CM = Cardiomyocyte 
CPC = Circulating progenitor cell 
CSC = Cardiac stem cell 
CSp = Cardiosphere 
CTE = Cardiac tissue engineering 
Cx43 = Connexin 43 
EC = Endothelial cell 
EPC = Endothelial progenitor cell 
EPDC = Epicardially derived cell 
ESC = Embryonic stem cell 
GCSF = Granulocyte colony stimulating factor 
GFP = Green fluorescent protein 
LV = Left ventricle 
MC = Mesothelial cell 
MHC = Myosin heavy chain 
MI = Myocardial infarction 
MSC = Mesenchymal stem cell 
PBSC = Peripheral blood stem cell 
Sca1 = Stem cell antigen 1 
SM = Skeletal myoblast 
SMA = Smooth muscle actin 
SMC = Smooth muscle cell 
SP = Side population 
SSEA1 = Stage specific embryonic antigen 1 
TnI = Troponin I 
UPC = Uncommitted precursor cell 
vWF = von Willebrand factor 
REFERENCES 
[1]  Dhalla, N.S.; Afzal, N.; Beamish, R.E.; Naimark, B.; Takeda, N.; 
Nagano, M. Pathophysiology of cardiac dysfunction in congestive 
heart failure. Can. J. Cardiol., 1993, 9(10), 873. 
[2]  Anversa, P.; Li, P.; Zhang, X.; Olivetti, G.; Capasso, J.M. Ischae-
mic myocardial injury and ventricular remodelling. Cardiovasc. 
Res., 1993, 27(2), 145. 
[3]  Udelson, J.E.; Patten, R.D.; Konstam, M.A. New concepts in post-
infarction ventricular remodeling. Rev. Cardiovasc. Med., 2003, 
4(Suppl. 3), S3. 
[4]  Burd, A.; Ahmed, K.; Lam, S.; Ayyappan, T.; Huang, L. Stem cell 
strategies in burns care. Burns, 2007, 33(3), 282. 
New Perspectives to Repair A Broken Heart Cardiovascular & Hematological Agents in Medicinal Chemistry, 2009, Vol. 7, No. 2    13 
[5]  Chen, F.H.; Rousche, K.T.; Tuan, R.S. Technology Insight: adult 
stem cells in cartilage regeneration and tissue engineering. Nat. 
Clin. Pract. Rheumatol., 2006, 2(7), 373. 
[6]  Corsi, K.A.; Schwarz, E.M.; Mooney, D.J.; Huard, J. Regenerative 
medicine in orthopaedic surgery. J. Orthop. Res., 2007, 25(10), 
1261. 
[7]  Stosich, M.S.; Mao, J.J. Adipose tissue engineering from human 
adult stem cells: clinical implications in plastic and reconstructive 
surgery. Plast. Reconstr. Surg., 2007, 119(1), 71. 
[8]  Gomillion, C.T.; Burg, K.J. Stem cells and adipose tissue engineer-
ing. Biomaterials, 2006, 27(36), 6052. 
[9]  Inatomi, T.; Nakamura, T.; Koizumi, N.; Sotozono, C.; Kinoshita, 
S. Current concepts and challenges in ocular surface reconstruction 
using cultivated mucosal epithelial transplantation. Cornea., 2005, 
24(8 Suppl.), S32. 
[10]  Boyle, A.J.; Schulman, S.P.; Hare, J.M.; Oettgen, P. Is stem cell 
therapy ready for patients? Stem Cell Therapy for Cardiac Repair. 
Ready for the Next Step. Circulation, 2006, 114(4), 339. 
[11]  Yoon, Y.S.; Lee, N.; Scadova, H. Myocardial regeneration with 
bone-marrow-derived stem cells. Biol. Cell, 2005, 97(4), 253. 
[12]  Laflamme, M.A.; Murry, C.E. Regenerating the heart. Nat. Bio-
technol., 2005, 23(7), 845. 
[13]  Guan, K.; Hasenfuss, G. Do stem cells in the heart truly differenti-
ate into cardiomyocytes? J. Mol. Cell Cardiol., 2007, 43(4), 377. 
[14]  Christoforou, N.; Gearhart, J.D. Stem cells and their potential in 
cell-based cardiac therapies. Prog. Cardiovasc. Dis., 2007, 49(6), 
396. 
[15]  Kocher, A.A.; Schlechta, B.; Gasparovicova, A.; Wolner, E.; Bon-
aros, N.; Laufer, G. Stem cells and cardiac regeneration. Transpl. 
Int., 2007, 20(9), 731. 
[16]  Zeisberg, E.M.; Tarnavski, O.; Zeisberg, M.; Dorfman, A.L.; 
McMullen, J.R.; Gustafsson, E.; Chandraker, A.; Yuan, X.; Pu, 
W.T.; Roberts, A.B.; Neilson, E.G.; Sayegh, M.H.; Izumo, S.; Kal-
luri, R. Endothelial-to-mesenchymal transition contributes to car-
diac fibrosis. Nat. Med., 2007, 13(8), 952. 
[17]  Siu, C.W.; Moore, J.C.; Li, R.A. Human embryonic stem cell-
derived cardiomyocytes for heart therapies. Cardiovasc. Hematol. 
Disord. Drug Targets, 2007, 7(2), 145. 
[18]  Skobel, E.; Schuh, A.; Schwarz, E.R.; Liehn, E.A.; Franke, A.; 
Breuer, S.; Gunther, K.; Reffelmann, T.; Hanrath, P.; Weber, C. 
Transplantation of fetal cardiomyocytes into infarcted rat hearts re-
sults in long-term functional improvement. Tissue Eng., 2004, 
10(5-6), 849. 
[19]  Caspi, O.; Huber, I.; Kehat, I.; Habib, M.; Arbel, G.; Gepstein, A.; 
Yankelson, L.; Aronson, D.; Beyar, R.; Gepstein, L. Transplanta-
tion of human embryonic stem cell-derived cardiomyocytes im-
proves myocardial performance in infarcted rat hearts. J. Am. Coll. 
Cardiol., 2007, 50(19), 1884. 
[20]  Guan, K.; Nayernia, K.; Maier, L.S.; Wagner, S.; Dressel, R.; Lee, 
J.H.; Nolte, J.; Wolf, F.; Li, M.; Engel, W.; Hasenfuss, G. Pluripo-
tency of spermatogonial stem cells from adult mouse testis. Nature, 
2006, 440(7088), 1199. 
[21]  Guan, K.; Wagner, S.; Unsold, B.; Maier, L.S.; Kaiser, D.; 
Hemmerlein, B.; Nayernia, K.; Engel, W.; Hasenfuss, G. Genera-
tion of functional cardiomyocytes from adult mouse spermatogo-
nial stem cells. Circ. Res., 2007, 100(11), 1615. 
[22]  Herrick, S.E.; Mutsaers, S.E. The potential of mesothelial cells in 
tissue engineering and regenerative medicine applications. Int. J. 
Artif. Organs, 2007, 30(6), 527. 
[23]  Elmadbouh, I.; Chen, Y.; Louedec, L.; Silberman, S.; Pouzet, B.; 
Meilhac, O.; Michel, J.B. Mesothelial cell transplantation in the in-
farct scar induces neovascularization and improves heart function. 
Cardiovasc. Res., 2005, 68(2), 307. 
[24]  Yu, J.; Vodyanik, M.A.; Smuga-Otto, K.; Antosiewicz-Bourget, J.; 
Frane, J.L.; Tian, S.; Nie, J.; Jonsdottir, G.A.; Ruotti, V.; Stewart, 
R.; Slukvin, II; Thomson, J. A. Induced pluripotent stem cell lines 
derived from human somatic cells. Science, 2007, 318(5858), 1917. 
[25]  Beltrami, A.P.; Urbanek, K.; Kajstura, J.; Yan, S.M.; Finato, N.; 
Bussani, R.; Nadal-Ginard, B.; Silvestri, F.; Leri, A.; Beltrami, 
C.A.; Anversa, P. Evidence that human cardiac myocytes divide af-
ter myocardial infarction. N. Engl. J. Med., 2001, 344(23), 1750. 
[26]  Hsieh, P.C.; Segers, V.F.; Davis, M.E.; MacGillivray, C.; Gannon, 
J.; Molkentin, J.D.; Robbins, J.; Lee, R.T. Evidence from a genetic 
fate-mapping study that stem cells refresh adult mammalian car-
diomyocytes after injury. Nat. Med., 2007, 13(8), 970. 
[27]  Chen, X.; Wilson, R.M.; Kubo, H.; Berretta, R.M.; Harris, D.M.; 
Zhang, X.; Jaleel, N.; MacDonnell, S.M.; Bearzi, C.; Tillmanns, J.; 
Trofimova, I.; Hosoda, T.; Mosna, F.; Cribbs, L.; Leri, A.; Kajstu-
ra, J.; Anversa, P.; Houser, S.R. Adolescent feline heart contains a 
population of small, proliferative ventricular myocytes with imma-
ture physiological properties. Circ. Res., 2007, 100(4), 536. 
[28]  Rota, M.; Hosoda, T.; De Angelis, A.; Arcarese, M.L.; Esposito, 
G.; Rizzi, R.; Tillmanns, J.; Tugal, D.; Musso, E.; Rimoldi, O.; 
Bearzi, C.; Urbanek, K.; Anversa, P.; Leri, A.; Kajstura, J. The y-
oung mouse heart is composed of myocytes heterogeneous in age 
and function. Circ. Res., 2007, 101(4), 387. 
[29]  Bhardwaj, R.D. Cytoarcheology: understanding cellular turnover in 
the human brain and hear. Dissertations from Karolinska Institutet, 
2007, (ISBN: 978-91-7357-130-2 ). 
[30]  Kuhn, B.; del Monte, F.; Hajjar, R.J.; Chang, Y.S.; Lebeche, D.; 
Arab, S.; Keating, M.T. Periostin induces proliferation of differen-
tiated cardiomyocytes and promotes cardiac repair. Nat. Med., 
2007, 13(8), 962. 
[31]  Curado, S.; Stainier, D.Y. The HeArt of regeneration. Cell, 2006, 
127(3), 462. 
[32]  Laube, F.; Heister, M.; Scholz, C.; Borchardt, T.; Braun, T. Re-
programming of newt cardiomyocytes is induced by tissue regen-
eration. J. Cell Sci., 2006, 119(Pt 22), 4719. 
[33]  Lepilina, A.; Coon, A.N.; Kikuchi, K.; Holdway, J.E.; Roberts, 
R.W.; Burns, C.G.; Poss, K. D. A dynamic epicardial injury re-
sponse supports progenitor cell activity during zebrafish heart re-
generation. Cell, 2006, 127(3), 607. 
[34]  Hierlihy, A.M.; Seale, P.; Lobe, C.G.; Rudnicki, M.A.; Megeney, 
L.A. The post-natal heart contains a myocardial stem cell popula-
tion. FEBS Lett., 2002, 530(1-3), 239. 
[35]  Martin, C.M.; Meeson, A.P.; Robertson, S.M.; Hawke, T.J.; 
Richardson, J.A.; Bates, S.; Goetsch, S.C.; Gallardo, T.D.; Garry, 
D.J. Persistent expression of the ATP-binding cassette transporter, 
Abcg2, identifies cardiac SP cells in the developing and adult heart. 
Dev. Biol., 2004, 265(1), 262. 
[36]  Pfister, O.; Mouquet, F.; Jain, M.; Summer, R.; Helmes, M.; Fine, 
A.; Colucci, W.S.; Liao, R. CD31- but Not CD31+ cardiac side 
population cells exhibit functional cardiomyogenic differentiation. 
Circ. Res., 2005, 97(1), 52. 
[37]  Beltrami, A.P.; Barlucchi, L.; Torella, D.; Baker, M.; Limana, F.; 
Chimenti, S.; Kasahara, H.; Rota, M.; Musso, E.; Urbanek, K.; 
Leri, A.; Kajstura, J.; Nadal-Ginard, B.; Anversa, P. Adult cardiac 
stem cells are multipotent and support myocardial regeneration. 
Cell, 2003, 114(6), 763. 
[38]  Dawn, B.; Stein, A.B.; Urbanek, K.; Rota, M.; Whang, B.; Ra-
staldo, R.; Torella, D.; Tang, X. L.; Rezazadeh, A.; Kajstura, J.; 
Leri, A.; Hunt, G.; Varma, J.; Prabhu, S.D.; Anversa, P.; Bolli, R. 
Cardiac stem cells delivered intravascularly traverse the vessel bar-
rier, regenerate infarcted myocardium, and improve cardiac func-
tion. Proc. Natl. Acad. Sci. USA, 2005, 102(10), 3766. 
[39]  Oh, H.; Bradfute, S.B.; Gallardo, T.D.; Nakamura, T.; Gaussin, V.; 
Mishina, Y.; Pocius, J.; Michael, L.H.; Behringer, R.R.; Garry, 
D.J.; Entman, M.L.; Schneider, M.D. Cardiac progenitor cells from 
adult myocardium: homing, differentiation, and fusion after infarc-
tion. Proc. Natl. Acad. Sci. USA, 2003, 100(21), 12313. 
[40]  Matsuura, K.; Nagai, T.; Nishigaki, N.; Oyama, T.; Nishi, J.; Wada, 
H.; Sano, M.; Toko, H.; Akazawa, H.; Sato, T.; Nakaya, H.; Kasa-
nuki, H.; Komuro, I. Adult cardiac Sca-1-positive cells differentiate 
into beating cardiomyocytes. J. Biol. Chem., 2004, 279(12), 11384. 
[41]  Laugwitz, K.L.; Moretti, A.; Lam, J.; Gruber, P.; Chen, Y.; Woo-
dard, S.; Lin, L.Z.; Cai, C.L.; Lu, M.M.; Reth, M.; Platoshyn, O.; 
Yuan, J.X.; Evans, S.; Chien, K.R. Postnatal isl1+ cardioblasts en-
ter fully differentiated cardiomyocyte lineages. Nature, 2005, 
433(7026), 647. 
[42]  Ott, H.C.; Matthiesen, T.S.; Brechtken, J.; Grindle, S.; Goh, S.K.; 
Nelson, W.; Taylor, D.A. The adult human heart as a source for 
stem cells: repair strategies with embryonic-like progenitor cells. 
Nat. Clin. Pract. Cardiovasc. Med., 2007, 4(Supp.l ), S27. 
[43]  Limana, F.; Zacheo, A.; Mocini, D.; Mangoni, A.; Borsellino, G.; 
Diamantini, A.; De Mori, R.; Battistini, L.; Vigna, E.; Santini, M.; 
Loiaconi, V.; Pompilio, G.; Germani, A.; Capogrossi, M.C. Identi-
fication of myocardial and vascular precursor cells in human and 
mouse epicardium. Circ. Res., 2007, 101(12), 1255. 
[44]  Messina, E.; De Angelis, L.; Frati, G.; Morrone, S.; Chimenti, S.; 
Fiordaliso, F.; Salio, M.; Battaglia, M.; Latronico, M.V.; Coletta, 
14    Cardiovascular & Hematological Agents in Medicinal Chemistry, 2009, Vol. 7, No. 2 Gaetani et al. 
M.; Vivarelli, E.; Frati, L.; Cossu, G.; Giacomello, A. Isolation and 
expansion of adult cardiac stem cells from human and murine he-
art. Circ. Res., 2004, 95(9), 911. 
[45]  Smith, R.R.; Barile, L.; Cho, H.C.; Leppo, M.K.; Hare, J.M.; Mes-
sina, E.; Giacomello, A.; Abraham, M.R.; Marban, E. Regenerative 
potential of cardiosphere-derived cells expanded from percutaneous 
endomyocardial biopsy specimens. Circulation, 2007, 115(7), 896. 
[46]  Garry, D.J.; Olson, E.N. A common progenitor at the heart of de-
velopment. Cell, 2006, 127(6), 1101. 
[47]  Moretti, A.; Caron, L.; Nakano, A.; Lam, J.T.; Bernshausen, A.; 
Chen, Y.; Qyang, Y.; Bu, L.; Sasaki, M.; Martin-Puig, S.; Sun, Y.; 
Evans, S.M.; Laugwitz, K.L.; Chien, K.R. Multipotent embryonic 
isl1+ progenitor cells lead to cardiac, smooth muscle, and endothe-
lial cell diversification. Cell, 2006, 127(6), 1151. 
[48]  Wu, S.M.; Fujiwara, Y.; Cibulsky, S.M.; Clapham, D.E.; Lien, 
C.L.; Schultheiss, T.M.; Orkin, S.H. Developmental origin of a 
bipotential myocardial and smooth muscle cell precursor in the 
mammalian heart. Cell, 2006, 127(6), 1137. 
[49]  Kattman, S.J.; Huber, T.L.; Keller, G.M. Multipotent flk-1+ car-
diovascular progenitor cells give rise to the cardiomyocyte, endo-
thelial, and vascular smooth muscle lineages. Dev. Cell, 2006, 
11(5), 723. 
[50]  Urbanek, K.; Cesselli, D.; Rota, M.; Nascimbene, A.; De Angelis, 
A.; Hosoda, T.; Bearzi, C.; Boni, A.; Bolli, R.; Kajstura, J.; Anver-
sa, P.; Leri, A. Stem cell niches in the adult mouse heart. Proc. 
Natl. Acad. Sci. USA, 2006, 103(24), 9226. 
[51]  Barile, L.; Cerisoli, F.; Gaetani, R.; Forte, E.; Ottolenghi, S.; Magli, 
M.C.; Messina, E. Cardiac stem cells can be generated in damaged 
heart from bone marrow-derived cells. J. Mole. Cell Cardiol., 
2007, 42(Suppl. 1), S100. 
[52]  Zammaretti, P.; Jaconi, M. Cardiac tissue engineering: regeneration 
of the wounded heart. Curr. Opin. Biotechnol., 2004, 15(5), 430. 
[53]  Zimmermann, W.H.; Didie, M.; Doker, S.; Melnychenko, I.; Naito, 
H.; Rogge, C.; Tiburcy, M.; Eschenhagen, T. Heart muscle engi-
neering: an update on cardiac muscle replacement therapy. Cardio-
vasc. Res., 2006, 71(3), 419. 
[54]  Jawad, H.; Ali, N.N.; Lyon, A.R.; Chen, Q.Z.; Harding, S.E.; Boc-
caccini, A.R. Myocardial tissue engineering: a review. J. Tissue 
Eng. Regen. Med., 2007, 1(5), 327. 
[55]  Leor, J.; Aboulafia-Etzion, S.; Dar, A.; Shapiro, L.; Barbash, I.M.; 
Battler, A.; Granot, Y.; Cohen, S. Bioengineered cardiac grafts: a 
new approach to repair the infarcted myocardium? Circulation, 
2000, 102(19 Suppl. 3), III56. 
[56]  Pego, A.P.; Van Luyn, M.J.; Brouwer, L.A.; van Wachem, P.B.; 
Poot, A.A.; Grijpma, D.W.; Feijen, J. In vivo behavior of poly(1,3-
trimethylene carbonate) and copolymers of 1,3-trimethylene car-
bonate with D,L-lactide or epsilon-caprolactone: degradation and 
tissue response. J. Biomed. Mater. Res. A, 2003, 67(3), 1044. 
[57]  Matsubayashi, K.; Fedak, P.W.; Mickle, D.A.; Weisel, R.D.; 
Ozawa, T.; Li, R.K. Improved left ventricular aneurysm repair with 
bioengineered vascular smooth muscle grafts. Circulation, 2003, 
108(Suppl. 1), II219. 
[58]  Piao, H.; Kwon, J.S.; Piao, S.; Sohn, J.H.; Lee, Y.S.; Bae, J.W.; 
Hwang, K.K.; Kim, D.W.; Jeon, O.; Kim, B.S.; Park, Y.B.; Cho, 
M.C. Effects of cardiac patches engineered with bone marrow-
derived mononuclear cells and PGCL scaffolds in a rat myocardial 
infarction model. Biomaterials, 2007, 28(4), 641. 
[59]  Shimizu, T.; Yamato, M.; Akutsu, T.; Shibata, T.; Isoi, Y.; Kiku-
chi, A.; Umezu, M.; Okano, T. Electrically communicating three-
dimensional cardiac tissue mimic fabricated by layered cultured 
cardiomyocyte sheets. J. Biomed. Mater. Res., 2002, 60(1), 110. 
[60]  Shimizu, T.; Yamato, M.; Isoi, Y.; Akutsu, T.; Setomaru, T.; Abe, 
K.; Kikuchi, A.; Umezu, M.; Okano, T. Fabrication of pulsatile 
cardiac tissue grafts using a novel 3-dimensional cell sheet 
manipulation technique and temperature-responsive cell culture 
surfaces. Circ. Res., 2002, 90(3), e40. 
[61]  Shimizu, T.; Yamato, M.; Kikuchi, A.; Okano, T. Cell sheet engi-
neering for myocardial tissue reconstruction. Biomaterials, 2003, 
24(13), 2309. 
[62]  Zimmermann, W.H.; Didie, M.; Wasmeier, G.H.; Nixdorff, U.; 
Hess, A.; Melnychenko, I.; Boy, O.; Neuhuber, W.L.; Weyand, M.; 
Eschenhagen, T. Cardiac grafting of engineered heart tissue in syn-
genic rats. Circulation, 2002, 106(12 Suppl. 1), I151. 
[63]  Zimmermann, W.H.; Melnychenko, I.; Wasmeier, G.; Didie, M.; 
Naito, H.; Nixdorff, U.; Hess, A.; Budinsky, L.; Brune, K.; Micha-
elis, B.; Dhein, S.; Schwoerer, A.; Ehmke, H.; Eschenhagen, T. 
Engineered heart tissue grafts improve systolic and diastolic func-
tion in infarcted rat hearts. Nat. Med., 2006, 12(4), 452. 
[64]  Kofidis, T.; Akhyari, P.; Boublik, J.; Theodorou, P.; Martin, U.; 
Ruhparwar, A.; Fischer, S.; Eschenhagen, T.; Kubis, H.P.; Kraft, 
T.; Leyh, R.; Haverich, A. In vitro engineering of heart muscle: ar-
tificial myocardial tissue. J. Thorac. Cardiovasc. Surg., 2002, 
124(1), 63. 
[65]  Kofidis, T.; Akhyari, P.; Wachsmann, B.; Boublik, J.; Mueller-
Stahl, K.; Leyh, R.; Fischer, S.; Haverich, A. A novel bioartificial 
myocardial tissue and its prospective use in cardiac surgery. Eur. J. 
Cardiothorac. Surg., 2002, 22(2), 238. 
[66]  Kofidis, T.; Lenz, A.; Boublik, J.; Akhyari, P.; Wachsmann, B.; 
Stahl, K.M.; Haverich, A.; Leyh, R.G. Bioartificial grafts for 
transmural myocardial restoration: a new cardiovascular tissue cul-
ture concept. Eur. J. Cardiothorac. Surg., 2003, 24(6), 906. 
[67]  Kofidis, T.; Akhyari, P.; Wachsmann, B.; Mueller-Stahl, K.; 
Boublik, J.; Ruhparwar, A.; Mertsching, H.; Balsam, L.; Robbins, 
R.; Haverich, A. Clinically established hemostatic scaffold (tissue 
fleece) as biomatrix in tissue- and organ-engineering research. Tis-
sue Eng., 2003, 9(3), 517. 
[68]  Kofidis, T.; de Bruin, J.L.; Hoyt, G.; Ho, Y.; Tanaka, M.; Yamane, 
T.; Lebl, D.R.; Swijnenburg, R.J.; Chang, C.P.; Quertermous, T.; 
Robbins, R.C. Myocardial restoration with embryonic stem cell 
bioartificial tissue transplantation. J. Heart Lung Transplant., 2005, 
24(6), 737. 
[69]  Cortes-Morichetti, M.; Frati, G.; Schussler, O.; Van Huyen, J.P.; 
Lauret, E.; Genovese, J.A.; Carpentier, A.F.; Chachques, J.C. As-
sociation between a cell-seeded collagen matrix and cellular car-
diomyoplasty for myocardial support and regeneration. Tissue 
Eng., 2007, 13(11), 2681. 
[70]  Akhyari, P.; Fedak, P.W.; Weisel, R.D.; Lee, T.Y.; Verma, S.; 
Mickle, D.A.; Li, R.K. Mechanical stretch regimen enhances the 
formation of bioengineered autologous cardiac muscle grafts. Cir-
culation, 2002, 106(12 Suppl. 1), I137. 
[71]  Chachques, J.C.; Trainini, J.C.; Lago, N.; Cortes-Morichetti, M.; 
Schussler, O.; Carpentier, A. Myocardial Assistance by Grafting a 
New Bioartificial Upgraded Myocardium (MAGNUM trial): clini-
cal feasibility study. Ann. Thorac. Surg., 2008, 85(3), 901. 
[72]  Christman, K.L.; Vardanian, A.J.; Fang, Q.; Sievers, R.E.; Fok, 
H.H.; Lee, R.J. Injectable fibrin scaffold improves cell transplant 
survival, reduces infarct expansion, and induces neovasculature 
formation in ischemic myocardium. J. Am. Coll. Cardiol., 2004, 
44(3), 654. 
[73]  Li, Y.S.; Gao, B.R. Transplantation of neonatal cardiomyocytes 
plus fibrin sealant restores myocardial function in a rat model of 
myocardial infarction. Chin. Med. J. (Engl.), 2007, 120(22), 2022. 
[74]  Huang, N.F.; Yu, J.; Sievers, R.; Li, S.; Lee, R.J. Injectable bio-
polymers enhance angiogenesis after myocardial infarction. Tissue 
Eng., 2005, 11(11-12), 1860. 
[75]  Suuronen, E.J.; Veinot, J.P.; Wong, S.; Kapila, V.; Price, J.; 
Griffith, M.; Mesana, T.G.; Ruel, M. Tissue-engineered injectable 
collagen-based matrices for improved cell delivery and vasculariza-
tion of ischemic tissue using CD133+ progenitors expanded from 
the peripheral blood. Circulation, 2006, 114(1 Supp. l), I138. 
[76]  Dai, W.; Wold, L.E.; Dow, J.S.; Kloner, R.A. Thickening of the 
infarcted wall by collagen injection improves left ventricular func-
tion in rats: a novel approach to preserve cardiac function after 
myocardial infarction. J. Am. Coll. Cardiol., 2005, 46(4), 714. 
[77]  Kutschka, I.; Chen, I.Y.; Kofidis, T.; Arai, T.; von Degenfeld, G.; 
Sheikh, A.Y.; Hendry, S. L.; Pearl, J.; Hoyt, G.; Sista, R.; Yang, 
P.C.; Blau, H.M.; Gambhir, S.S.; Robbins, R.C. Collagen matrices 
enhance survival of transplanted cardiomyoblasts and contribute to 
functional improvement of ischemic rat hearts. Circulation, 2006, 
114(1 Suppl.), I167. 
[78]  Kofidis, T.; Lebl, D.R.; Martinez, E.C.; Hoyt, G.; Tanaka, M.; 
Robbins, R.C. Novel injectable bioartificial tissue facilitates tar-
geted, less invasive, large-scale tissue restoration on the beating 
heart after myocardial injury. Circulation, 2005, 112(9 Suppl.), 
I173. 
[79]  Davis, M.E.; Motion, J.P.; Narmoneva, D.A.; Takahashi, T.; Ha-
kuno, D.; Kamm, R.D.; Zhang, S.; Lee, R.T. Injectable self-
assembling peptide nanofibers create intramyocardial microenvi-
ronments for endothelial cells. Circulation, 2005, 111(4), 442. 
New Perspectives to Repair A Broken Heart Cardiovascular & Hematological Agents in Medicinal Chemistry, 2009, Vol. 7, No. 2    15 
[80]  Perin, E.C.; Lopez, J. Methods of stem cell delivery in cardiac 
diseases. Nat. Clin. Pract. Cardiovasc. Med., 2006, 3(Suppl. 1), 
S110. 
[81]  Dimmeler, S.; Zeiher, A.M.; Schneider, M.D. Unchain my heart: 
the scientific foundations of cardiac repair. J. Clin. Invest., 2005, 
115(3), 572. 
[82]  Davani, S.; Deschaseaux, F.; Chalmers, D.; Tiberghien, P.; Kante-
lip, J.P. Can stem cells mend a broken heart? Cardiovasc. Res., 
2005, 65(2), 305. 
[83]  Ince, H.; Petzsch, M.; Kleine, H.D.; Schmidt, H.; Rehders, T.; 
Korber, T.; Schumichen, C.; Freund, M.; Nienaber, C.A. Preserva-
tion from left ventricular remodeling by front-integrated revascu-
larization and stem cell liberation in evolving acute myocardial in-
farction by use of granulocyte-colony-stimulating factor (FIRST-
LINE-AMI). Circulation, 2005, 112(20), 3097. 
[84].  Ince, H.; Petzsch, M.; Kleine, H.D.; Eckard, H.; Rehders, T.; Bur-
ska, D.; Kische, S.; Freund, M.; Nienaber, C.A. Prevention of left 
ventricular remodeling with granulocyte colony-stimulating factor 
after acute myocardial infarction: final 1-year results of the Front-
Integrated Revascularization and Stem Cell Liberation in Evolving 
Acute Myocardial Infarction by Granulocyte Colony-Stimulating 
Factor (FIRSTLINE-AMI) Trial. Circulation, 2005, 112(9 Suppl.), 
I73. 
[85]  Engelmann, M.G.; Theiss, H.D.; Hennig-Theiss, C.; Huber, A.; 
Wintersperger, B.J.; Werle-Ruedinger, A.E.; Schoenberg, S.O.; 
Steinbeck, G.; Franz, W.M. Autologous bone marrow stem cell 
mobilization induced by granulocyte colony-stimulating factor after 
subacute ST-segment elevation myocardial infarction undergoing 
late revascularization: final results from the G-CSF-STEMI 
(Granulocyte Colony-Stimulating Factor ST-Segment Elevation 
Myocardial Infarction) trial. J. Am. Coll. Cardiol., 2006, 48(8), 
1712. 
[86]  Ripa, R.S.; Jorgensen, E.; Wang, Y.; Thune, J.J.; Nilsson, J.C.; 
Sondergaard, L.; Johnsen, H. E.; Kober, L.; Grande, P.; Kastrup, J. 
Stem cell mobilization induced by subcutaneous granulocyte-
colony stimulating factor to improve cardiac regeneration after 
acute ST-elevation myocardial infarction: result of the double-
blind, randomized, placebo-controlled stem cells in myocardial in-
farction (STEMMI) trial. Circulation, 2006, 113(16), 1983. 
[87]  Ripa, R.S.; Haack-Sorensen, M.; Wang, Y.; Jorgensen, E.; Mort-
ensen, S.; Bindslev, L.; Friis, T.; Kastrup, J. Bone marrow derived 
mesenchymal cell mobilization by granulocyte-colony stimulating 
factor after acute myocardial infarction: results from the Stem Cells 
in Myocardial Infarction (STEMMI) trial. Circulation, 2007, 
116(11 Suppl.), I24. 
[88]  Zohlnhofer, D.; Ott, I.; Mehilli, J.; Schomig, K.; Michalk, F.; Ibra-
him, T.; Meisetschlager, G.; von Wedel, J.; Bollwein, H.; Seyfarth, 
M.; Dirschinger, J.; Schmitt, C.; Schwaiger, M.; Kastrati, A.; 
Schomig, A. Stem cell mobilization by granulocyte colony-
stimulating factor in patients with acute myocardial infarction: a 
randomized controlled trial. JAMA, 2006, 295(9), 1003. 
[89]  Menasche, P.; Hagege, A.A.; Vilquin, J.T.; Desnos, M.; Abergel, 
E.; Pouzet, B.; Bel, A.; Sarateanu, S.; Scorsin, M.; Schwartz, K.; 
Bruneval, P.; Benbunan, M.; Marolleau, J.P.; Duboc, D. Autolo-
gous skeletal myoblast transplantation for severe postinfarction left 
ventricular dysfunction. J. Am. Coll. Cardiol., 2003, 41(7), 1078. 
[90]  Pagani, F.D.; DerSimonian, H.; Zawadzka, A.; Wetzel, K.; Edge, 
A.S.; Jacoby, D.B.; Dinsmore, J.H.; Wright, S.; Aretz, T.H.; Eisen, 
H.J.; Aaronson, K.D. Autologous skeletal myoblasts transplanted to 
ischemia-damaged myocardium in humans. Histological analysis of 
cell survival and differentiation. J. Am. Coll. Cardiol., 2003, 41(5), 
879. 
[91]  Hagege, A.A.; Vilquin, J.T.; Bruneval, P.; Menasche, P. Regenera-
tion of the myocardium: a new role in the treatment of ischemic 
heart disease? Hypertension, 2001, 38(6), 1413. 
[92]  Makkar, R.R.; Lill, M.; Chen, P.S. Stem cell therapy for myocar-
dial repair: is it arrhythmogenic? J. Am. Coll. Cardiol., 2003, 
42(12), 2070. 
[93]  Abraham, M.R.; Henrikson, C.A.; Tung, L.; Chang, M.G.; Aon, 
M.; Xue, T.; Li, R.A.; B, O. R.; Marban, E. Antiarrhythmic engi-
neering of skeletal myoblasts for cardiac transplantation. Circ Res, 
2005, 97(2), 159. 
[94]  Rubart, M.; Soonpaa, M.H.; Nakajima, H.; Field, L.J. Spontaneous 
and evoked intracellular calcium transients in donor-derived myo-
cytes following intracardiac myoblast transplantation. J. Clin. In-
vest., 2004, 114(6), 775. 
[95]  Assmus, B.; Schachinger, V.; Teupe, C.; Britten, M.; Lehmann, R.; 
Dobert, N.; Grunwald, F.; Aicher, A.; Urbich, C.; Martin, H.; Hoel-
zer, D.; Dimmeler, S.; Zeiher, A.M. Transplantation of Progenitor 
Cells and Regeneration Enhancement in Acute Myocardial Infarc-
tion (TOPCARE-AMI). Circulation, 2002, 106(24), 3009. 
[96]  Schachinger, V.; Assmus, B.; Britten, M.B.; Honold, J.; Lehmann, 
R.; Teupe, C.; Abolmaali, N.D.; Vogl, T.J.; Hofmann, W.K.; Mar-
tin, H.; Dimmeler, S.; Zeiher, A.M. Transplantation of progenitor 
cells and regeneration enhancement in acute myocardial infarction: 
final one-year results of the TOPCARE-AMI Trial. J. Am. Coll. 
Cardiol., 2004, 44(8), 1690. 
[97]  Wollert, K.C.; Meyer, G.P.; Lotz, J.; Ringes-Lichtenberg, S.; Lip-
polt, P.; Breidenbach, C.; Fichtner, S.; Korte, T.; Hornig, B.; Mes-
singer, D.; Arseniev, L.; Hertenstein, B.; Ganser, A.; Drexler, H. 
Intracoronary autologous bone-marrow cell transfer after myocar-
dial infarction: the BOOST randomised controlled clinical trial. 
Lancet, 2004, 364(9429), 141. 
[98]  Meyer, G.P.; Wollert, K.C.; Lotz, J.; Steffens, J.; Lippolt, P.; Ficht-
ner, S.; Hecker, H.; Schaefer, A.; Arseniev, L.; Hertenstein, B.; 
Ganser, A.; Drexler, H. Intracoronary bone marrow cell transfer af-
ter myocardial infarction: eighteen months' follow-up data from the 
randomized, controlled BOOST (BOne marrOw transfer to enhance 
ST-elevation infarct regeneration) trial. Circulation, 2006, 113(10), 
1287. 
[99]  Orlic, D.; Kajstura, J.; Chimenti, S.; Jakoniuk, I.; Anderson, S.M.; 
Li, B.; Pickel, J.; McKay, R.; Nadal-Ginard, B.; Bodine, D.M.; 
Leri, A.; Anversa, P. Bone marrow cells regenerate infarcted myo-
cardium. Nature, 2001, 410(6829), 701. 
[100]  Kajstura, J.; Rota, M.; Whang, B.; Cascapera, S.; Hosoda, T.; 
Bearzi, C.; Nurzynska, D.; Kasahara, H.; Zias, E.; Bonafe, M.; 
Nadal-Ginard, B.; Torella, D.; Nascimbene, A.; Quaini, F.; Ur-
banek, K.; Leri, A.; Anversa, P. Bone marrow cells differentiate in 
cardiac cell lineages after infarction independently of cell fusion. 
Circ. Res., 2005, 96(1), 127. 
[101]  Jackson, K.A.; Majka, S.M.; Wang, H.; Pocius, J.; Hartley, C.J.; 
Majesky, M.W.; Entman, M. L.; Michael, L.H.; Hirschi, K.K.; 
Goodell, M.A. Regeneration of ischemic cardiac muscle and vascu-
lar endothelium by adult stem cells. J. Clin. Invest., 2001, 107(11), 
1395. 
[102]  Murry, C.E.; Soonpaa, M.H.; Reinecke, H.; Nakajima, H.; Naka-
jima, H.O.; Rubart, M.; Pasumarthi, K.B.; Virag, J.I.; Bartelmez, 
S.H.; Poppa, V.; Bradford, G.; Dowell, J.D.; Williams, D. A.; 
Field, L.J. Haematopoietic stem cells do not transdifferentiate into 
cardiac myocytes in myocardial infarcts. Nature, 2004, 428(6983), 
664. 
[103]  Balsam, L.B.; Wagers, A.J.; Christensen, J.L.; Kofidis, T.; Weiss-
man, I.L.; Robbins, R.C. Haematopoietic stem cells adopt mature 
haematopoietic fates in ischaemic myocardium. Nature, 2004, 
428(6983), 668. 
[104]  Pittenger, M.F.; Mackay, A.M.; Beck, S.C.; Jaiswal, R.K.; Doug-
las, R.; Mosca, J.D.; Moorman, M.A.; Simonetti, D.W.; Craig, S.; 
Marshak, D.R. Multilineage potential of adult human mesenchymal 
stem cells. Science, 1999, 284(5411), 143. 
[105]  Amado, L.C.; Saliaris, A.P.; Schuleri, K.H.; St John, M.; Xie, J.S.; 
Cattaneo, S.; Durand, D.J.; Fitton, T.; Kuang, J.Q.; Stewart, G.; 
Lehrke, S.; Baumgartner, W.W.; Martin, B.J.; Heldman, A.W.; 
Hare, J.M. Cardiac repair with intramyocardial injection of alloge-
neic mesenchymal stem cells after myocardial infarction. Proc. 
Natl. Acad. Sci. USA, 2005, 102(32), 11474. 
[106]  Hou, M.; Yang, K.M.; Zhang, H.; Zhu, W.Q.; Duan, F.J.; Wang, 
H.; Song, Y.H.; Wei, Y.J.; Hu, S.S. Transplantation of mesenchy-
mal stem cells from human bone marrow improves damaged heart 
function in rats. Int. J. Cardiol., 2007, 115(2), 220. 
[107]  Dai, W.; Hale, S.L.; Martin, B.J.; Kuang, J.Q.; Dow, J.S.; Wold, 
L.E.; Kloner, R.A. Allogeneic mesenchymal stem cell transplanta-
tion in postinfarcted rat myocardium: short- and long-term effects. 
Circulation, 2005, 112(2), 214. 
[108]  Toma, C.; Pittenger, M.F.; Cahill, K.S.; Byrne, B.J.; Kessler, P.D. 
Human mesenchymal stem cells differentiate to a cardiomyocyte 
phenotype in the adult murine heart. Circulation, 2002, 105(1), 93. 
[109]  Shake, J.G.; Gruber, P.J.; Baumgartner, W.A.; Senechal, G.; Mey-
ers, J.; Redmond, J.M.; Pittenger, M.F.; Martin, B.J. Mesenchymal 
stem cell implantation in a swine myocardial infarct model: en-
16    Cardiovascular & Hematological Agents in Medicinal Chemistry, 2009, Vol. 7, No. 2 Gaetani et al. 
graftment and functional effects. Ann. Thorac. Surg., 2002, 73(6), 
1919. 
[110]  Kawamoto, A.; Gwon, H.C.; Iwaguro, H.; Yamaguchi, J.I.; Uchida, 
S.; Masuda, H.; Silver, M.; Ma, H.; Kearney, M.; Isner, J.M.; Asa-
hara, T. Therapeutic potential of ex vivo expanded endothelial pro-
genitor cells for myocardial ischemia. Circulation, 2001, 103(5), 
634. 
[111]  Kocher, A.A.; Schuster, M.D.; Szabolcs, M.J.; Takuma, S.; Burk-
hoff, D.; Wang, J.; Homma, S.; Edwards, N.M.; Itescu, S. Neovas-
cularization of ischemic myocardium by human bone-marrow-
derived angioblasts prevents cardiomyocyte apoptosis, reduces re-
modeling and improves cardiac function. Nat. Med., 2001, 7(4), 
430. 
[112]  Iwasaki, H.; Kawamoto, A.; Ishikawa, M.; Oyamada, A.; Na-
kamori, S.; Nishimura, H.; Sadamoto, K.; Horii, M.; Matsumoto, 
T.; Murasawa, S.; Shibata, T.; Suehiro, S.; Asahara, T. Dose-
dependent contribution of CD34-positive cell transplantation to 
concurrent vasculogenesis and cardiomyogenesis for functional re-
generative recovery after myocardial infarction. Circulation, 2006, 
113(10), 1311. 
[113].  Reinecke, H.; Poppa, V.; Murry, C.E. Skeletal muscle stem cells do 
not transdifferentiate into cardiomyocytes after cardiac grafting. J. 
Mol. Cell Cardiol., 2002, 34(2), 241. 
[114]  Ghostine, S.; Carrion, C.; Souza, L.C.; Richard, P.; Bruneval, P.; 
Vilquin, J.T.; Pouzet, B.; Schwartz, K.; Menasche, P.; Hagege, 
A.A. Long-term efficacy of myoblast transplantation on regional 
structure and function after myocardial infarction. Circulation, 
2002, 106(12 Suppl. 1), I131. 
[115]  Bearzi, C.; Rota, M.; Hosoda, T.; Tillmanns, J.; Nascimbene, A.; 
De Angelis, A.; Yasuzawa-Amano, S.; Trofimova, I.; Siggins, 
R.W.; Lecapitaine, N.; Cascapera, S.; Beltrami, A.P.; D'Alessan-
dro, D.A.; Zias, E.; Quaini, F.; Urbanek, K.; Michler, R.E.; Bolli, 
R.; Kajstura, J.; Leri, A.; Anversa, P. Human cardiac stem cells. 
Proc. Natl. Acad. Sci. USA, 2007, 104(35), 14068. 
[116]  Strauer, B.E.; Brehm, M.; Zeus, T.; Kostering, M.; Hernandez, A.; 
Sorg, R.V.; Kogler, G.; Wernet, P. Repair of infarcted myocardium 
by autologous intracoronary mononuclear bone marrow cell trans-
plantation in humans. Circulation, 2002, 106(15), 1913. 
[117]  Assmus, B.; Honold, J.; Schachinger, V.; Britten, M.B.; Fischer-
Rasokat, U.; Lehmann, R.; Teupe, C.; Pistorius, K.; Martin, H.; 
Abolmaali, N.D.; Tonn, T.; Dimmeler, S.; Zeiher, A.M. Transcoro-
nary transplantation of progenitor cells after myocardial infarction. 
N. Engl. J. Med., 2006, 355(12), 1222. 
[118]  Assmus, B.; Fischer-Rasokat, U.; Honold, J.; Seeger, F.H.; 
Fichtlscherer, S.; Tonn, T.; Seifried, E.; Schachinger, V.; Dimme-
ler, S.; Zeiher, A.M. Transcoronary transplantation of functionally 
competent BMCs is associated with a decrease in natriuretic pep-
tide serum levels and improved survival of patients with chronic 
postinfarction heart failure: results of the TOPCARE-CHD Regis-
try. Circ. Res., 2007, 100(8), 1234. 
[119].  Schachinger, V.; Erbs, S.; Elsasser, A.; Haberbosch, W.; 
Hambrecht, R.; Holschermann, H.; Yu, J.; Corti, R.; Mathey, D. G.; 
Hamm, C. W.; Suselbeck, T.; Assmus, B.; Tonn, T.; Dimmeler, S.; 
Zeiher, A. M. Intracoronary bone marrow-derived progenitor cells 
in acute myocardial infarction. N. Engl. J. Med., 2006, 355(12), 
1210. 
[120]  Schachinger, V.; Erbs, S.; Elsasser, A.; Haberbosch, W.; Ham-
brecht, R.; Holschermann, H.; Yu, J.; Corti, R.; Mathey, D.G.; 
Hamm, C.W.; Suselbeck, T.; Werner, N.; Haase, J.; Neuzner, J.; 
Germing, A.; Mark, B.; Assmus, B.; Tonn, T.; Dimmeler, S.; Zei-
her, A.M. Improved clinical outcome after intracoronary admini-
stration of bone-marrow-derived progenitor cells in acute myocar-
dial infarction: final 1-year results of the REPAIR-AMI trial. Eur. 
Heart J., 2006, 27(23), 2775. 
[121]  Fernandez-Aviles, F.; San Roman, J.A.; Garcia-Frade, J.; Fernan-
dez, M.E.; Penarrubia, M.J.; de la Fuente, L.; Gomez-Bueno, M.; 
Cantalapiedra, A.; Fernandez, J.; Gutierrez, O.; Sanchez, P.L.; 
Hernandez, C.; Sanz, R.; Garcia-Sancho, J.; Sanchez, A. Experi-
mental and clinical regenerative capability of human bone marrow 
cells after myocardial infarction. Circ. Res., 2004, 95(7), 742. 
[122]  Strauer, B.E.; Brehm, M.; Zeus, T.; Bartsch, T.; Schannwell, C.; 
Antke, C.; Sorg, R.V.; Kogler, G.; Wernet, P.; Muller, H.W.; Kos-
tering, M. Regeneration of human infarcted heart muscle by intra-
coronary autologous bone marrow cell transplantation in chronic 
coronary artery disease: the IACT Study. J. Am. Coll. Cardiol., 
2005, 46(9), 1651. 
[123]  Janssens, S.; Dubois, C.; Bogaert, J.; Theunissen, K.; Deroose, C.; 
Desmet, W.; Kalantzi, M.; Herbots, L.; Sinnaeve, P.; Dens, J.; 
Maertens, J.; Rademakers, F.; Dymarkowski, S.; Gheysens, O.; 
Van Cleemput, J.; Bormans, G.; Nuyts, J.; Belmans, A.; Mortel-
mans, L.; Boogaerts, M.; Van de Werf, F. Autologous bone mar-
row-derived stem-cell transfer in patients with ST-segment eleva-
tion myocardial infarction: double-blind, randomised controlled 
trial. Lancet, 2006, 367(9505), 113. 
[124]  Lunde, K.; Solheim, S.; Aakhus, S.; Arnesen, H.; Abdelnoor, M.; 
Forfang, K. Autologous stem cell transplantation in acute myocar-
dial infarction: The ASTAMI randomized controlled trial. Intra-
coronary transplantation of autologous mononuclear bone marrow 
cells, study design and safety aspects. Scand. Cardiovasc. J., 2005, 
39(3), 150. 
[125]  Lunde, K.; Solheim, S.; Aakhus, S.; Arnesen, H.; Abdelnoor, M.; 
Egeland, T.; Endresen, K.; Ilebekk, A.; Mangschau, A.; Fjeld, J. 
G.; Smith, H. J.; Taraldsrud, E.; Grogaard, H. K.; Bjornerheim, R.; 
Brekke, M.; Muller, C.; Hopp, E.; Ragnarsson, A.; Brinchmann, J. 
E.; Forfang, K. Intracoronary injection of mononuclear bone mar-
row cells in acute myocardial infarction. N. Engl. J. Med., 2006, 
355(12), 1199. 
[126]  Chen, S.L.; Fang, W.W.; Ye, F.; Liu, Y.H.; Qian, J.; Shan, S.J.; 
Zhang, J.J.; Chunhua, R.Z.; Liao, L.M.; Lin, S.; Sun, J.P. Effect on 
left ventricular function of intracoronary transplantation of autolo-
gous bone marrow mesenchymal stem cell in patients with acute 
myocardial infarction. Am. J. Cardiol., 2004, 94(1), 92. 
[127]  Katritsis, D.G.; Sotiropoulou, P.A.; Karvouni, E.; Karabinos, I.; 
Korovesis, S.; Perez, S.A.; Voridis, E.M.; Papamichail, M. 
Transcoronary transplantation of autologous mesenchymal stem 
cells and endothelial progenitors into infarcted human myocardium. 
Catheter. Cardiovasc. Interv., 2005, 65(3), 321. 
[128]  Tse, H.F.; Kwong, Y.L.; Chan, J.K.; Lo, G.; Ho, C.L.; Lau, C.P. 
Angiogenesis in ischaemic myocardium by intramyocardial autolo-
gous bone marrow mononuclear cell implantation. Lancet, 2003, 
361(9351), 47. 
[129]  Perin, E.C.; Dohmann, H.F.; Borojevic, R.; Silva, S.A.; Sousa, 
A.L.; Mesquita, C.T.; Rossi, M.I.; Carvalho, A.C.; Dutra, H.S.; 
Dohmann, H.J.; Silva, G.V.; Belem, L.; Vivacqua, R.; Rangel, F. 
O.; Esporcatte, R.; Geng, Y.J.; Vaughn, W.K.; Assad, J.A.; Mes-
quita, E.T.; Willerson, J.T. Transendocardial, autologous bone mar-
row cell transplantation for severe, chronic ischemic heart failure. 
Circulation, 2003, 107(18), 2294. 
[130]  Perin, E.C.; Dohmann, H.F.; Borojevic, R.; Silva, S.A.; Sousa, 
A.L.; Silva, G.V.; Mesquita, C. T.; Belem, L.; Vaughn, W.K.; 
Rangel, F.O.; Assad, J.A.; Carvalho, A.C.; Branco, R.V.; Rossi, 
M.I.; Dohmann, H.J.; Willerson, J.T. Improved exercise capacity 
and ischemia 6 and 12 months after transendocardial injection of 
autologous bone marrow mononuclear cells for ischemic cardio-
myopathy. Circulation, 2004, 110(11 Suppl. 1), II213. 
[131]  Fuchs, S.; Satler, L.F.; Kornowski, R.; Okubagzi, P.; Weisz, G.; 
Baffour, R.; Waksman, R.; Weissman, N.J.; Cerqueira, M.; Leon, 
M.B.; Epstein, S.E. Catheter-based autologous bone marrow myo-
cardial injection in no-option patients with advanced coronary ar-
tery disease: a feasibility study. J. Am. Coll. Cardiol., 2003, 41(10), 
1721. 
[132]  Stamm, C.; Westphal, B.; Kleine, H.D.; Petzsch, M.; Kittner, C.; 
Klinge, H.; Schumichen, C.; Nienaber, C.A.; Freund, M.; Steinhoff, 
G. Autologous bone-marrow stem-cell transplantation for myocar-
dial regeneration. Lancet, 2003, 361(9351), 45. 
[133]  Stamm, C.; Kleine, H.D.; Westphal, B.; Petzsch, M.; Kittner, C.; 
Nienaber, C.A.; Freund, M.; Steinhoff, G. CABG and bone marrow 
stem cell transplantation after myocardial infarction. Thorac. 
Cardiovasc. Surg., 2004, 52(3), 152. 
[134]  Li, T.S.; Hamano, K.; Hirata, K.; Kobayashi, T.; Nishida, M. The 
safety and feasibility of the local implantation of autologous bone 
marrow cells for ischemic heart disease. J. Card. Surg., 2003, 
18(Suppl. 2), S69. 
[135]  Kang, H.J.; Kim, H.S.; Zhang, S.Y.; Park, K.W.; Cho, H.J.; Koo, 
B.K.; Kim, Y.J.; Soo Lee, D.; Sohn, D.W.; Han, K.S.; Oh, B.H.; 
Lee, M.M.; Park, Y.B. Effects of intracoronary infusion of periph-
eral blood stem-cells mobilised with granulocyte-colony stimulat-
ing factor on left ventricular systolic function and restenosis after 
New Perspectives to Repair A Broken Heart Cardiovascular & Hematological Agents in Medicinal Chemistry, 2009, Vol. 7, No. 2    17 
coronary stenting in myocardial infarction: the MAGIC cell ran-
domised clinical trial. Lancet, 2004, 363(9411), 751. 
[136]  Kang, H.J.; Lee, H.Y.; Na, S.H.; Chang, S.A.; Park, K.W.; Kim, 
H.K.; Kim, S.Y.; Chang, H. J.; Lee, W.; Kang, W.J.; Koo, B.K.; 
Kim, Y.J.; Lee, D.S.; Sohn, D.W.; Han, K.S.; Oh, B.H.; Park, Y. 
B.; Kim, H.S. Differential effect of intracoronary infusion of mobi-
lized peripheral blood stem cells by granulocyte colony-stimulating 
factor on left ventricular function and remodeling in patients with 
acute myocardial infarction versus old myocardial infarction: the 
MAGIC Cell-3-DES randomized, controlled trial. Circulation, 
2006, 114(1 Suppl.), I145. 
[137]  Erbs, S.; Linke, A.; Adams, V.; Lenk, K.; Thiele, H.; Diederich, 
K.W.; Emmrich, F.; Kluge, R.; Kendziorra, K.; Sabri, O.; Schuler, 
G.; Hambrecht, R. Transplantation of blood-derived progenitor 
cells after recanalization of chronic coronary artery occlusion: first 
randomized and placebo-controlled study. Circ. Res., 2005, 97(8), 
756. 
[138]  Erbs, S.; Linke, A.; Schuler, G.; Hambrecht, R. Intracoronary ad-
ministration of circulating blood-derived progenitor cells after re-
canalization of chronic coronary artery occlusion improves endo-
thelial function. Circ. Res., 2006, 98(5), e48. 
[139]  Boyle, A.J.; Whitbourn, R.; Schlicht, S.; Krum, H.; Kocher, A.; 
Nandurkar, H.; Bergmann, S.; Daniell, M.; O'Day, J.; Skerrett, D.; 
Haylock, D.; Gilbert, R. E.; Itescu, S. Intra-coronary high-dose 
CD34+ stem cells in patients with chronic ischemic heart disease: a 
12-month follow-up. Int. J. Cardiol., 2006, 109(1), 21. 
[140]  Ozbaran, M.; Omay, S.B.; Nalbantgil, S.; Kultursay, H.; Kuman-
lioglu, K.; Nart, D.; Pektok, E. Autologous peripheral stem cell 
transplantation in patients with congestive heart failure due to 
ischemic heart disease. Eur. J. Cardiothorac. Surg., 2004, 25(3), 
342. 
[141]  Pompilio, G.; Cannata, A.; Peccatori, F.; Bertolini, F.; Nascimbene, 
A.; Capogrossi, M.C.; Biglioli, P. Autologous peripheral blood 
stem cell transplantation for myocardial regeneration: a novel stra-
tegy for cell collection and surgical injection. Ann. Thorac. Surg., 
2004, 78(5), 1808. 
[142]  Losordo, D.W.; Schatz, R.A.; White, C.J.; Udelson, J.E.; Veere-
shwarayya, V.; Durgin, M.; Poh, K.K.; Weinstein, R.; Kearney, M.; 
Chaudhry, M.; Burg, A.; Eaton, L.; Heyd, L.; Thorne, T.; Shtur-
man, L.; Hoffmeister, P.; Story, K.; Zak, V.; Dowling, D.; Traver-
se, J.H.; Olson, R.E.; Flanagan, J.; Sodano, D.; Murayama, T.; Ka-
wamoto, A.; Kusano, K. F.; Wollins, J.; Welt, F.; Shah, P.; Soukas, 
P.; Asahara, T.; Henry, T.D. Intramyocardial transplantation of au-
tologous CD34+ stem cells for intractable angina: a phase I/IIa 
double-blind, randomized controlled trial. Circulation, 2007, 
115(25), 3165. 
[143]  Briguori, C.; Reimers, B.; Sarais, C.; Napodano, M.; Pascotto, P.; 
Azzarello, G.; Bregni, M.; Porcellini, A.; Vinante, O.; Zanco, P.; 
Peschle, C.; Condorelli, G.; Colombo, A. Direct intramyocardial 
percutaneous delivery of autologous bone marrow in patients with 
refractory myocardial angina. Am. Heart J., 2006, 151(3), 674. 
[144]  Herreros, J.; Prosper, F.; Perez, A.; Gavira, J.J.; Garcia-Velloso, 
M.J.; Barba, J.; Sanchez, P. L.; Canizo, C.; Rabago, G.; Marti-
Climent, J.M.; Hernandez, M.; Lopez-Holgado, N.; Gonzalez-
Santos, J.M.; Martin-Luengo, C.; Alegria, E. Autologous intramyo-
cardial injection of cultured skeletal muscle-derived stem cells in 
patients with non-acute myocardial infarction. Eur. Heart J., 2003, 
24(22), 2012. 
[145]  Gavira, J.J.; Herreros, J.; Perez, A.; Garcia-Velloso, M.J.; Barba, J.; 
Martin-Herrero, F.; Canizo, C.; Martin-Arnau, A.; Marti-Climent, 
J.M.; Hernandez, M.; Lopez-Holgado, N.; Gonzalez-Santos, J. M.; 
Martin-Luengo, C.; Alegria, E.; Prosper, F. Autologous skeletal 
myoblast transplantation in patients with nonacute myocardial in-
farction: 1-year follow-up. J. Thorac. Cardiovasc. Surg., 2006, 
131(4), 799. 
[146]  Siminiak, T.; Kalawski, R.; Fiszer, D.; Jerzykowska, O.; Rzeznic-
zak, J.; Rozwadowska, N.; Kurpisz, M. Autologous skeletal myo-
blast transplantation for the treatment of postinfarction myocardial 
injury: phase I clinical study with 12 months of follow-up. Am. 
Heart J., 2004, 148(3), 531. 
[147]  Dib, N.; Michler, R.E.; Pagani, F.D.; Wright, S.; Kereiakes, D.J.; 
Lengerich, R.; Binkley, P.; Buchele, D.; Anand, I.; Swingen, C.; Di 
Carli, M.F.; Thomas, J.D.; Jaber, W.A.; Opie, S.R.; Campbell, A.; 
McCarthy, P.; Yeager, M.; Dilsizian, V.; Griffith, B.P.; Korn, R.; 
Kreuger, S.K.; Ghazoul, M.; MacLellan, W.R.; Fonarow, G.; Eisen, 
H.J.; Dinsmore, J.; Diethrich, E. Safety and feasibility of autolo-
gous myoblast transplantation in patients with ischemic cardiomy-
opathy: four-year follow-up. Circulation, 2005, 112(12), 1748. 
[148]  Smits, P.C.; van Geuns, R.J.; Poldermans, D.; Bountioukos, M.; 
Onderwater, E.E.; Lee, C. H.; Maat, A.P.; Serruys, P.W. Catheter-
based intramyocardial injection of autologous skeletal myoblasts as 
a primary treatment of ischemic heart failure: clinical experience 
with six-month follow-up. J. Am. Coll. Cardiol., 2003, 42(12), 
2063. 
[149]  Ince, H.; Petzsch, M.; Rehders, T.C.; Chatterjee, T.; Nienaber, C.A. 
Transcatheter transplantation of autologous skeletal myoblasts in 
postinfarction patients with severe left ventricular dysfunction. J. 
Endovasc. Ther., 2004, 11(6), 695. 
[150]  Siminiak, T.; Fiszer, D.; Jerzykowska, O.; Grygielska, B.; Roz-
wadowska, N.; Kalmucki, P.; Kurpisz, M. Percutaneous trans-
coronary-venous transplantation of autologous skeletal myoblasts 
in the treatment of post-infarction myocardial contractility impair-
ment: the POZNAN trial. Eur. Heart J., 2005, 26(12), 1188.  
 
Received: 4 December, 2007 Revised: 20 March, 2008 Accepted: 1 April, 2008 
 
